51
|
Dam Lauridsen M, Rorth R, Butt JH, Schmidt M, Kristensen SL, Kragholm K, Johnsen SP, Moller JE, Hassager C, Kober LV, Fosbol EL. Home care provision and nursing home admission after myocardial infarction in relation to cardiogenic shock and out-of-hospital cardiac arrest status. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Autonomy is of great importance for quality of life. There is a paucity of data on autonomy for those who survive myocardial infarction (MI) with and without cardiogenic shock (CS) and out-of-hospital arrest (OHCA).
Purpose
To examine the association between CS, OHCA, and need for home care provision or nursing home admission as a proxy for impaired autonomy in a first-time MI population.
Methods
Danish nationwide registries were used to identify patients with first-time MI (2009–2019), who prior to the event were living at home without home care and discharged alive. The patients were stratified according to CS and OHCA status. We report 1-year cumulative incidence of a composite outcome of home care provision or nursing home admission with competing risk of death and as a secondary outcome all-cause mortality. Cause specific Cox regression models were used to estimate adjusted hazard ratios (HR) with patients without CS or OHCA as reference.
Results
We identified 61,451 patients in the period with MI (by groups: −OHCA/−CS: 59,316, −OHCA/+CS: 1,597, +OHCA/−CS: 913, and +OHCA/+CS: 669). The 1-year cumulative incidences of home care/nursing home were 6.9% for patients with −OHCA/−CS, 21.1% for −OHCA/+CS, 5.2% for +OHCA/−CS, and 8.1% for those with +OHCA/+CS. With the −OHCA/−CS as reference, the adjusted HRs for home care/nursing home were 3.12 (95% CI: 2.78–3.49) for patients with −OHCA/+CS, 1.27 (95% CI: 0.95–1.70) for +OHCA/−CS, and 2.31 (95% CI: 1.76–3.03) for +OHCA/+CS (Figure). The 1-year cumulative incidences of mortality were 4.8% for patients with −OHCA/−CS, 10.0% for −OHCA/+CS, 2.8% for +OHCA/−CS, and 3.7% for those with +OHCA/+CS (adjusted HRs: 2.81 (95% CI: 2.55–3.10), 1.09 (95% CI: 0.85–1.39) and 1.81 (95% CI: 1.42–2.30) (Figure 1).
Conclusion
In a selected cohort of patients with MI, without previous need for home care/nursing home and surviving until discharge date, patients with CS were independent of OHCA status associated with less autonomy after discharge with a more than two-fold higher 1-year incidence of home care provision or nursing home admission. Further, patients with CS were associated with a two-fold higher 1-year mortality compared with MI patients without CS independent of OHCA status.
Funding Acknowledgement
Type of funding sources: Public hospital(s). Main funding source(s): The work was supported by Rigshospitalets Research Foundation, Master cabinetmaker Sophus Jacobsen and Wife Astrid Jacobsen Foundation, and Director Jacob Madsen and Wife Olga Madsens Foundation. The funding source had no role in the design, conduct, analysis, or reporting of the study.
Collapse
|
52
|
Schmidt M, Arendt-Nielsen L, Hauge EM, Soerensen HT, Pedersen L. Dose-dependency of diclofenac's cardiovascular risks: a series of nationwide emulated trials. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2730] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
The dose dependency of the adverse effects of diclofenac remains poorly understood.
Purpose
To examine the dose-related cardiovascular risks associated with diclofenac initiation
Methods
We used Danish nationwide health registries (1999–2018) to conduct a series of emulated trials (n=285). Eligible adults had no recent NSAID fillings, contraindications, or conditions with low adherence. Individuals eligible for inclusion were ≥18 years with (1) ≥90 days continuous prescription records prior to diclofenac initiation (baseline); (2) no NSAID prescriptions ≤90 days before enrollment, and (3) no exclusion criteria. Exclusion criteria reflected likelihood of low adherence to treatment (dementia, schizophrenia, or antipsychotic drug use) and labeled contraindications (ulcer disease/anti-ulcer drugs, gastrointestinal bleeding, inflammatory bowel disease, thrombocytopenia, or heart failure). Initiators of diclofenac were compared to healthcare-seeking non-initiators, but also head-to-head for initiators of high (≥75 mg pills as proxy for ≥150 mg/daily) vs. low dose (≤50 mg pills as proxy for <150 mg/daily). Cox proportional-hazards regression was used to compute the intention-to-treat hazard ratio, as measure of the incidence rate ratio (IRR), of major adverse cardiac and cerebrovascular events (MACCE) within 30 days from initiation.
Results
Among 3,177,484 diclofenac initiatiors, 31% used high and 69% used low dose. Compared with non-initiators, diclofenac initiatiors had a 70% increased rate for MACCE (IRR 1.70, 95% CI: 1.55–1.86), reflecting for the individual MACCE components an increased IRRs of 1.66 (95% CI: 1.54–1.79) for myocardial infaction, 1.32 (1.20–1.45) for ischemic stroke, and 1.69 (1.54–1.86) for cardiac death. The effect for MACCE did not differ between initiators of high (IRR 1.73, 95% CI: 1.51–1.97) and low dose (IRR 1.68, 95% CI: 1.52–1.86) (Figure 1). When comparing high and low dose diclofenac head-to-head, we found no meaningful difference in the IRR for MACCE (1.03, 95% CI: 0.89–1.19), MI (0.99, 0.87–1.11), ischemic stroke (0.95, 0.81–1.11) or cardiac death (1.04, 0.90–1.21) (Figure 2).
Conclusion
Initiation of low- and high-dose diclofenac was associated with a consistent and comparable increase in cardiovascular risk.
Funding Acknowledgement
Type of funding sources: Foundation. Main funding source(s): Novo Nordisk Foundation
Collapse
|
53
|
Bonnesen K, Szepligeti SK, Heide-Jorgensen U, Sorensen HT, Schmidt M. The interaction effect of CHA2DS2-VASc components on ischemic stroke risk after atrial fibrillation: a population-based cohort study. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
In the European Union, almost nine million individuals 55 years or older had atrial fibrillation in 2010. It is estimated that around a quarter of all ischemic stroke cases in individuals 80 to 89 years can be attributed to atrial fibrillation. The CHA2DS2-VASc is the most commonly used clinical tool to predict ischemic stroke and incorporates congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke/transient ischemic attack/systemic embolism, vascular disease, age 65 to 74 years, and female sex. It remains unknown whether the CHA2DS2-VASc components and atrial fibrillation interact biologically, i.e. whether the CHA2DS2-VASc components and atrial fibrillation increase ischemic stroke rate beyond their individual effects.
Purpose
We examined the interaction effect between CHA2DS2-VASc and atrial fibrillation and on ischemic stroke rate.
Methods
We conducted a population-based cohort study of all adult atrial fibrillation or flutter patients from 1996 through 2016 and a one-to-five comparison cohort from the general population. Members of the comparison cohort were matched on year of birth, sex, and the individual CHA2DS2-VASc components. We followed each individual from the index date (the date of atrial fibrillation or date of matching) until the first of ischemic stroke, death from any cause, loss-to follow-up, 10 years follow-up, or 31 December 2016. We calculated ischemic stroke rates per 1,000 person-years (PYs) and interaction contrasts, which is the proportion of the summed ischemic stroke rate of the CHA2DS2-VASc components and atrial fibrillation that is beyond their individual effects.
Results
After one-year follow-up, the ischemic stroke rate per 1,000 PY among individuals with CHA2DS2-VASc score zero was 5.69 (95% confidence interval [CI]: 4.68–6.69) in the atrial fibrillation cohort and 1.86 (95% CI: 1.60–2.12) in the comparison cohort. Among individuals with CHA2DS2-VASc score one, the mortality rate per 1,000 PY increased to 10.9 (95% CI: 9.75–12.0) in the atrial fibrillation cohort and 7.45 (95% CI: 7.01–7.88) in the comparison cohort. The interaction contrast in individuals with CHA2DS2-VASc score one was −0.41 (10.8 − 7.45 − 5.69 + 1.86) indicating that the ischemic stroke rate was not explained by interaction (−0.41 / 10.8 = −3.8%). The interaction effect was −2.75 in individuals with CHA2DS2-VASc score two and −2.79 in individuals with CHA2DS2-VASc score three or higher, again indicating no interaction. Interaction did not explain the ischemic stroke rate after one to five years follow-up either, but did explain 16% of the ischemic stroke rate in individuals with CHA2DS2-VASc score three or higher after five to 10 years follow-up.
Conclusion
Biological interaction between the CHA2DS2-VASc components and atrial fibrillation does not contribute substantially to the ischemic stroke risk.
Funding Acknowledgement
Type of funding sources: None.
Collapse
|
54
|
Bonnesen K, Klok FA, Andersen MJ, Andersen A, Nielsen-Kudsk JE, Mellemkjaer S, Sorensen HT, Schmidt M. Chronic thromboembolic pulmonary hypertension and mortality after venous thromboembolism: a nationwide population-based cohort study. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background
One of the ultimate long-term complications of venous thromboembolism (VTE) is chronic thromboembolic pulmonary hypertension (CTEPH). CTEPH is a condition defined as an increased mean pulmonary arterial pressure of at least 25 mmHg at rest and abnormal pulmonary artery resistance measured by right heart catheterization. To our knowledge, no study has compared mortality in VTE patients developing CTEPH to those who do not.
Purpose
We aimed to investigate the influence of CTEPH on long-term VTE mortality, by examining how receiving any pulmonary hypertension (PH) diagnosis following VTE influenced mortality.
Methods
We conducted a population-based cohort study of all adult Danish patients with an incident in or outpatient VTE diagnosis from 1995 through 2016. We excluded patients with a previous PH diagnosis. We defined CTEPH as receiving any PH diagnosis within two years following VTE. We categorized VTE by type (deep venous thrombosis [DVT] or pulmonary embolism [PE]) and provoking risk factors. We followed patients from two years after VTE until the first of death, emigration, or 31 December 2016. We calculated mortality rates and standardized mortality rate ratios (SMRs) of the association between PH and all-cause mortality and cause-specific mortality due to cancer and cardiovascular diseases. We also stratified the analyses by baseline presence of comorbidity (congestive heart failure, chronic pulmonary disease, and/or interstitial pulmonary disease).
Results
In 89,062 VTE patients alive two years after their VTE, 724 developed PH. The mortality rate per 1,000 person-years was 121 (95% confidence interval [CI]: 110–134) in patients with PH and 48 (95% CI: 47–48) in patients without PH. The SMR was 2.05 (95% CI: 1.77–2.37) for all VTE patients, 2.20 (95% CI: 1.53–3.16) for DVT patients, and 1.72 (95% CI: 1.47–2.01) for PE patients. The SMR was 1.79 (95% CI: 1.28–2.51) in VTE patients with a provoking VTE risk factor and 2.15 (95% CI: 1.83–2.53) in VTE patients without a provoking VTE risk factor. PH was associated with increased cause-specific mortality due to cardiovascular diseases (SMR=2.31, 95% CI: 1.75–3.06), but not cancer (SMR=0.94, 95% CI: 0.64–1.38). The SMR was 2.36 (95% CI: 2.06–2.71) in patients with comorbidity and 1.80 (95% CI: 1.45–2.24) in patients without comorbidity.
Conclusion
Development of PH, as a measure of CTEPH, within two years following incident VTE was associated with two-fold increased mortality in two-year VTE survivors. The increase in mortality was driven by cardiovascular causes.
Funding Acknowledgement
Type of funding sources: None.
Collapse
|
55
|
Bonnesen K, Heide-Jorgensen U, Schmidt M. Potential of comorbidity indices and CHA2DS2-VASc to predict ischemic stroke and mortality in patients with atrial fibrillation: a validation study. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Atrial fibrillation represents a large health burden and increases the risk of ischemic stroke and mortality. A large proportion of atrial fibrillation patients also has other comorbidities. It remains unknown whether comorbidity burden summarized as a comorbidity score can predict ischemic stroke and mortality after atrial fibrillation. In an aging population burdened with comorbidities, it thus has become increasingly important to understand the impact of comorbidity burden on the prognosis of atrial fibrillation.
Purpose
We examined the ability of the Danish Comorbidity Index for Acute Myocardial Infarction (DANCAMI), the Charlson Comorbidity Index (CCI), the Elixhauser Comorbidity Index (ECI), and the CHA2DS2-VASc to predict ischemic stroke and all-cause mortality within one year after atrial fibrillation or flutter.
Methods
We identified all patients with a first-time atrial fibrillation or flutter hospital diagnosis in Denmark from 2000 through 2015 (n=318,939). We identified all comorbidities in each index using hospital diagnoses in the 10 years before diagnosis of atrial fibrillation or flutter. For each comorbidity index, we calculated Harrell's C-Statistic to predict ischemic stroke, all-cause mortality, and cause-specific mortality due to cardiovascular diseases and cancer within one year after atrial fibrillation or flutter. We also calculated hazard ratios of the association of the DANCAMI comorbidities not included in the CCI with ischemic stroke and all-cause mortality within one year after atrial fibrillation or flutter, after conditioning on age, sex, and all CCI comorbidities.
Results
The C-Statistic to predict ischemic stroke was 0.64 (95% confidence interval [CI]: 0.63–0.64) for DANCAMI, 0.63 (95% CI: 0.63–0.64) for CCI, 0.63 (95% CI: 0.63–0.64) for ECI, and 0.64 (95% CI: 0.63–0.64) for CHA2DS2-VASc. The C-Statistic to predict all-cause mortality was 0.74 (95% CI: 0.74–0.75) for DANCAMI, 0.74 (95% CI: 0.73–0.74) for CCI, 0.73 (95% CI: 0.72–0.73) for ECI, and 0.69 (95% CI: 0.69–0.69) for CHA2DS2-VASc. Among the DANCAMI comorbidities not included in the CCI, five predicted increased risk of ischemic stroke (epilepsy, alcohol and drug abuse, schizophrenia, affective disorder, and chronic kidney disease) and eight predicted increased risk of all-cause mortality (coagulopathy, neurodegenerative disorder, epilepsy, alcohol and drug abuse, schizophrenia, affective disorder, chronic kidney disease, and chronic pancreatitis). Compared with all-cause mortality, DANCAMI was better at predicting mortality due to cardiovascular diseases (C-Statistic=0.79, 95% CI: 0.79–0.80) and cancer (C-Statistic=0.78, 95% CI: 95% CI: 0.76–0.80)
Conclusion
In patients with first-time atrial fibrillation or flutter, no comorbidity index predicted ischemic stroke well. However, DANCAMI predicted all-cause mortality on a par with the CCI and the ECI and better than CHA2DS2-VASc.
Funding Acknowledgement
Type of funding sources: None.
Collapse
|
56
|
Schmidt M. The Effect of Education on Hydration Status of Several Female Collegiate Teams at Southern Utah University. J Acad Nutr Diet 2022. [DOI: 10.1016/j.jand.2022.08.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
57
|
Geyer C, Garber J, Gelber R, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong A, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek S, Eisen A, Elsafy F, Fein L, Fielding A, Ford J, Friedman S, Gelmon K, Gianni L, Gnant M, Hollingsworth S, Im SA, Jager A, Jóhannsson Ó, Lakhani S, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas P, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer C, Španić T, Stickeler E, Toi M, Traina T, Viale G, Zoppoli G, Park Y, Yerushalmi R, Yang H, Pang D, Jung K, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke G, Sun Q, Parton M, Colleoni M, Schmidt M, Brufsky A, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt A. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer. Ann Oncol 2022; 33:1250-1268. [PMID: 36228963 DOI: 10.1016/j.annonc.2022.09.159] [Citation(s) in RCA: 123] [Impact Index Per Article: 61.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Accepted: 09/22/2022] [Indexed: 01/10/2023] Open
Abstract
BACKGROUND The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic variants in germline BRCA1 or BRCA2 (gBRCA1/2pv) and high-risk, human epidermal growth factor receptor 2-negative, early breast cancer (EBC). The first pre-specified interim analysis (IA) previously demonstrated statistically significant improvement in invasive disease-free survival (IDFS) and distant disease-free survival (DDFS). The olaparib group had fewer deaths than the placebo group, but the difference did not reach statistical significance for overall survival (OS). We now report the pre-specified second IA of OS with updates of IDFS, DDFS, and safety. PATIENTS AND METHODS One thousand eight hundred and thirty-six patients were randomly assigned to olaparib or placebo following (neo)adjuvant chemotherapy, surgery, and radiation therapy if indicated. Endocrine therapy was given concurrently with study medication for hormone receptor-positive cancers. Statistical significance for OS at this IA required P < 0.015. RESULTS With a median follow-up of 3.5 years, the second IA of OS demonstrated significant improvement in the olaparib group relative to the placebo group [hazard ratio 0.68; 98.5% confidence interval (CI) 0.47-0.97; P = 0.009]. Four-year OS was 89.8% in the olaparib group and 86.4% in the placebo group (Δ 3.4%, 95% CI -0.1% to 6.8%). Four-year IDFS for the olaparib group versus placebo group was 82.7% versus 75.4% (Δ 7.3%, 95% CI 3.0% to 11.5%) and 4-year DDFS was 86.5% versus 79.1% (Δ 7.4%, 95% CI 3.6% to 11.3%), respectively. Subset analyses for OS, IDFS, and DDFS demonstrated benefit across major subgroups. No new safety signals were identified including no new cases of acute myeloid leukemia or myelodysplastic syndrome. CONCLUSION With 3.5 years of median follow-up, OlympiA demonstrates statistically significant improvement in OS with adjuvant olaparib compared with placebo for gBRCA1/2pv-associated EBC and maintained improvements in the previously reported, statistically significant endpoints of IDFS and DDFS with no new safety signals.
Collapse
|
58
|
Acharya S, Adamová D, Adler A, Adolfsson J, Aglieri Rinella G, Agnello M, Agrawal N, Ahammed Z, Ahmad S, Ahn S, Ahuja I, Akbar Z, Akindinov A, Al-Turany M, Alam S, Aleksandrov D, Alessandro B, Alfanda H, Alfaro Molina R, Ali B, Ali Y, Alici A, Alizadehvandchali N, Alkin A, Alme J, Alocco G, Alt T, Altsybeev I, Anaam M, Andrei C, Andreou D, Andronic A, Anguelov V, Antinori F, Antonioli P, Anuj C, Apadula N, Aphecetche L, Appelshäuser H, Arcelli S, Arnaldi R, Arsene I, Arslandok M, Augustinus A, Averbeck R, Aziz S, Azmi M, Badalà A, Baek Y, Bai X, Bailhache R, Bailung Y, Bala R, Balbino A, Baldisseri A, Balis B, Banerjee D, Banoo Z, Barbera R, Barioglio L, Barlou M, Barnaföldi G, Barnby L, Barret V, Bartels C, Barth K, Bartsch E, Baruffaldi F, Bastid N, Basu S, Batigne G, Battistini D, Batyunya B, Bauri D, Bazo Alba J, Bearden I, Beattie C, Becht P, Belikov I, Bell Hechavarria A, Bellini F, Bellwied R, Belokurova S, Belyaev V, Bencedi G, Beole S, Bercuci A, Berdnikov Y, Berdnikova A, Bergmann L, Besoiu M, Betev L, Bhaduri P, Bhasin A, Bhat I, Bhat M, Bhattacharjee B, Bhattacharya P, Bianchi L, Bianchi N, Yamaguchi Y, Yamakawa K, Yang S, Yano S, Yin Z, Yoo IK, Yoon J, Yuan S, Yuncu A, Zaccolo V, Bielčík J, Zampolli C, Zanoli H, Zanone F, Zardoshti N, Zarochentsev A, Závada P, Zaviyalov N, Zhalov M, Zhang B, Zhang S, Bielčíková J, Zhang X, Zhang Y, Zherebchevskii V, Zhi Y, Zhigareva N, Zhou D, Zhou Y, Zhu J, Zhu Y, Zinovjev G, Biernat J, Zurlo N, Bilandzic A, Biro G, Biswas S, Blair J, Blau D, Blidaru M, Blume C, Boca G, Bock F, Bogdanov A, Boi S, Bok J, Boldizsár L, Bolozdynya A, Bombara M, Bond P, Bonomi G, Borel H, Borissov A, Bossi H, Botta E, Bratrud L, Braun-Munzinger P, Bregant M, Broz M, Bruno G, Buckland M, Budnikov D, Buesching H, Bufalino S, Bugnon O, Buhler P, Buthelezi Z, Butt J, Bylinkin A, Bysiak S, Cai M, Caines H, Caliva A, Calvo Villar E, Camacho J, Camacho R, Camerini P, Canedo F, Carabas M, Carnesecchi F, Caron R, Castillo Castellanos J, Casula E, Catalano F, Ceballos Sanchez C, Chakaberia I, Chakraborty P, Chandra S, Chapeland S, Chartier M, Chattopadhyay S, Chattopadhyay S, Chavez T, Cheng T, Cheshkov C, Cheynis B, Chibante Barroso V, Chinellato D, Cho S, Chochula P, Christakoglou P, Christensen C, Christiansen P, Chujo T, Cicalo C, Cifarelli L, Cindolo F, Ciupek M, Clai G, Cleymans J, Colamaria F, Colburn J, Colella D, Collu A, Colocci M, Concas M, Conesa Balbastre G, Conesa del Valle Z, Contin G, Contreras J, Coquet M, Cormier T, Cortese P, Cosentino M, Costa F, Costanza S, Crochet P, Cruz-Torres R, Cuautle E, Cui P, Cunqueiro L, Dainese A, Danisch M, Danu A, Das P, Das P, Das S, Dash S, De Caro A, de Cataldo G, De Cilladi L, de Cuveland J, De Falco A, De Gruttola D, De Marco N, De Martin C, De Pasquale S, Deb S, Degenhardt H, Deja K, Del Grande R, Dello Stritto L, Deng W, Dhankher P, Di Bari D, Di Mauro A, Diaz R, Dietel T, Ding Y, Divià R, Dixit D, Djuvsland Ø, Dmitrieva U, Do J, Dobrin A, Dönigus B, Dubey A, Dubla A, Dudi S, Dupieux P, Durkac M, Dzalaiova N, Eder T, Ehlers R, Eikeland V, Eisenhut F, Elia D, Erazmus B, Ercolessi F, Erhardt F, Erokhin A, Ersdal M, Espagnon B, Eulisse G, Evans D, Evdokimov S, Fabbietti L, Faggin M, Faivre J, Fan F, Fan W, Fantoni A, Fasel M, Fecchio P, Feliciello A, Feofilov G, Fernández Téllez A, Ferrero A, Ferretti A, Feuillard V, Figiel J, Filova V, Finogeev D, Fionda F, Fiorenza G, Flor F, Flores A, Foertsch S, Fokin S, Fragiacomo E, Frajna E, Francisco A, Fuchs U, Funicello N, Furget C, Furs A, Gaardhøje J, Gagliardi M, Gago A, Gal A, Galvan C, Ganoti P, Garabatos C, Garcia J, Garcia-Solis E, Garg K, Gargiulo C, Garibli A, Garner K, Gasik P, Gauger E, Gautam A, Gay Ducati M, Germain M, Ghosh S, Giacalone M, Gianotti P, Giubellino P, Giubilato P, Glaenzer A, Glässel P, Glimos E, Goh D, Gonzalez V, González-Trueba L, Gorbunov S, Gorgon M, Görlich L, Gotovac S, Grabski V, Graczykowski L, Greiner L, Grelli A, Grigoras C, Grigoriev V, Grigoryan S, Grosa F, Grosse-Oetringhaus J, Grosso R, Grund D, Guardiano G, Guernane R, Guilbaud M, Gulbrandsen K, Gunji T, Guo W, Gupta A, Gupta R, Guzman S, Gyulai L, Habib M, Hadjidakis C, Haidenbauer J, Hamagaki H, Hamid M, Hannigan R, Haque M, Harlenderova A, Harris J, Harton A, Hasenbichler J, Hassan H, Hatzifotiadou D, Hauer P, Havener L, Heckel S, Hellbär E, Helstrup H, Herman T, Herrera Corral G, Herrmann F, Hetland K, Heybeck B, Hillemanns H, Hills C, Hippolyte B, Hofman B, Hohlweger B, Honermann J, Hong G, Horak D, Hornung S, Horzyk A, Hosokawa R, Hou Y, Hristov P, Hughes C, Huhn P, Huhta L, Hulse C, Humanic T, Hushnud H, Husova L, Hutson A, Hyodo T, Iddon J, Ilkaev R, Ilyas H, Inaba M, Innocenti G, Ippolitov M, Isakov A, Isidori T, Islam M, Ivanov M, Ivanov V, Izucheev V, Jablonski M, Jacak B, Jacazio N, Jacobs P, Jadlovska S, Jadlovsky J, Jaelani S, Jahnke C, Jakubowska M, Jalotra A, Janik M, Janson T, Jercic M, Jevons O, Jimenez A, Jonas F, Jones P, Jowett J, Jung J, Jung M, Junique A, Jusko A, Kabus M, Kaewjai J, Kalinak P, Kalteyer A, Kalweit A, Kamiya Y, Kaplin V, Karasu Uysal A, Karatovic D, Karavichev O, Karavicheva T, Karczmarczyk P, Karpechev E, Kashyap V, Kazantsev A, Kebschull U, Keidel R, Keijdener D, Keil M, Ketzer B, Khan A, Khan S, Khanzadeev A, Kharlov Y, Khatun A, Khuntia A, Kileng B, Kim B, Kim C, Kim D, Kim E, Kim J, Kim J, Kim J, Kim J, Kim M, Kim S, Kim T, Kirsch S, Kisel I, Kiselev S, Kisiel A, Kitowski J, Klay J, Klein J, Klein S, Klein-Bösing C, Kleiner M, Klemenz T, Kluge A, Knospe A, Kobdaj C, Kollegger T, Kondratyev A, Kondratyeva N, Kondratyuk E, Konig J, Konigstorfer S, Konopka P, Kornakov G, Koryciak S, Kotliarov A, Kovalenko O, Kovalenko V, Kowalski M, Králik I, Kravčáková A, Kreis L, Krivda M, Krizek F, Krizkova Gajdosova K, Kroesen M, Krüger M, Krupova D, Kryshen E, Krzewicki M, Kučera V, Kuhn C, Kuijer P, Kumaoka T, Kumar D, Kumar L, Kumar N, Kundu S, Kurashvili P, Kurepin A, Kurepin A, Kuryakin A, Kushpil S, Kvapil J, Kweon M, Kwon J, Kwon Y, La Pointe S, La Rocca P, Lai Y, Lakrathok A, Lamanna M, Langoy R, Larionov P, Laudi E, Lautner L, Lavicka R, Lazareva T, Lea R, Lehrbach J, Lemmon R, León Monzón I, Lesch M, Lesser E, Lettrich M, Lévai P, Li X, Li X, Lien J, Lietava R, Lim B, Lim S, Lindenstruth V, Lindner A, Lippmann C, Liu A, Liu D, Liu J, Lofnes I, Loginov V, Loizides C, Loncar P, Lopez J, Lopez X, López Torres E, Luhder J, Lunardon M, Luparello G, Ma Y, Maevskaya A, Mager M, Mahmoud T, Maire A, Malaev M, Malik N, Malik Q, Malik S, Malinina L, Mal’Kevich D, Mallick D, Mallick N, Mandaglio G, Manko V, Manso F, Manzari V, Mao Y, Margagliotti G, Margotti A, Marín A, Markert C, Marquard M, Martin N, Martinengo P, Martinez J, Martínez M, Martínez García G, Masciocchi S, Masera M, Masoni A, Massacrier L, Mastroserio A, Mathis A, Matonoha O, Matuoka P, Matyja A, Mayer C, Mazuecos A, Mazzaschi F, Mazzilli M, Mdhluli J, Mechler A, Melikyan Y, Menchaca-Rocha A, Meninno E, Menon A, Meres M, Mhlanga S, Miake Y, Micheletti L, Migliorin L, Mihaylov D, Mikhaylov K, Mishra A, Miśkowiec D, Modak A, Mohanty A, Mohanty B, Mohisin Khan M, Molander M, Moravcova Z, Mordasini C, Moreira De Godoy D, Morozov I, Morsch A, Mrnjavac T, Muccifora V, Mudnic E, Mühlheim D, Muhuri S, Mulligan J, Mulliri A, Munhoz M, Munzer R, Murakami H, Murray S, Musa L, Musinsky J, Myrcha J, Naik B, Nair R, Nandi B, Nania R, Nappi E, Nassirpour A, Nath A, Nattrass C, Neagu A, Negru A, Nellen L, Nesbo S, Neskovic G, Nesterov D, Nielsen B, Nielsen E, Nikolaev S, Nikulin S, Nikulin V, Noferini F, Noh S, Nomokonov P, Norman J, Novitzky N, Nowakowski P, Nyanin A, Nystrand J, Ogino M, Ohlson A, Ohnishi A, Okorokov V, Oleniacz J, Oliveira Da Silva A, Oliver M, Onnerstad A, Oppedisano C, Ortiz Velasquez A, Osako T, Oskarsson A, Otwinowski J, Oya M, Oyama K, Pachmayer Y, Padhan S, Pagano D, Paić G, Palasciano A, Panebianco S, Park J, Parkkila J, Pathak S, Patra R, Paul B, Pei H, Peitzmann T, Peng X, Pereira L, Pereira Da Costa H, Peresunko D, Perez G, Perrin S, Pestov Y, Petráček V, Petrov V, Petrovici M, Pezzi R, Piano S, Pikna M, Pillot P, Pinazza O, Pinsky L, Pinto C, Pisano S, Płoskoń M, Planinic M, Pliquett F, Poghosyan M, Polichtchouk B, Politano S, Poljak N, Pop A, Porteboeuf-Houssais S, Porter J, Pozdniakov V, Prasad S, Preghenella R, Prino F, Pruneau C, Pshenichnov I, Puccio M, Qiu S, Quaglia L, Quishpe R, Ragoni S, Rakotozafindrabe A, Ramello L, Rami F, Ramirez S, Rancien T, Raniwala R, Raniwala S, Räsänen S, Rath R, Ravasenga I, Read K, Redelbach A, Redlich K, Rehman A, Reichelt P, Reidt F, Reme-ness H, Rescakova Z, Reygers K, Riabov A, Riabov V, Richert T, Richter M, Riegler W, Riggi F, Ristea C, Rodríguez Cahuantzi M, Røed K, Rogalev R, Rogochaya E, Rogoschinski T, Rohr D, Röhrich D, Rojas P, Rojas Torres S, Rokita P, Ronchetti F, Rosano A, Rosas E, Rossi A, Roy A, Roy P, Roy S, Rubini N, Rueda O, Ruggiano D, Rui R, Rumyantsev B, Russek P, Russo R, Rustamov A, Ryabinkin E, Ryabov Y, Rybicki A, Rytkonen H, Rzesa W, Saarimaki O, Sadek R, Sadovsky S, Saetre J, Šafařík K, Saha S, Saha S, Sahoo B, Sahoo P, Sahoo R, Sahoo S, Sahu D, Sahu P, Saini J, Sakai S, Salvan M, Sambyal S, Saramela T, Sarkar D, Sarkar N, Sarma P, Sarti V, Sas M, Schambach J, Scheid H, Schiaua C, Schicker R, Schmah A, Schmidt C, Schmidt H, Schmidt M, Schmidt M, Schmidt N, Schmier A, Schotter R, Schukraft J, Schwarz K, Schweda K, Scioli G, Scomparin E, Seger J, Sekiguchi Y, Sekihata D, Selyuzhenkov I, Senyukov S, Seo J, Serebryakov D, Šerkšnytė L, Sevcenco A, Shaba T, Shabanov A, Shabetai A, Shahoyan R, Shaikh W, Shangaraev A, Sharma A, Sharma D, Sharma H, Sharma M, Sharma N, Sharma S, Sharma U, Shatat A, Sheibani O, Shigaki K, Shimomura M, Shirinkin S, Shou Q, Sibiriak Y, Siddhanta S, Siemiarczuk T, Silva T, Silvermyr D, Simantathammakul T, Simonetti G, Singh B, Singh R, Singh R, Singh R, Singh V, Singhal V, Sinha T, Sitar B, Sitta M, Skaali T, Skorodumovs G, Slupecki M, Smirnov N, Snellings R, Soncco C, Song J, Songmoolnak A, Soramel F, Sorensen S, Sputowska I, Stachel J, Stan I, Steffanic P, Stiefelmaier S, Stocco D, Storehaug I, Storetvedt M, Stratmann P, Strazzi S, Stylianidis C, Suaide A, Suire C, Sukhanov M, Suljic M, Sultanov R, Sumberia V, Sumowidagdo S, Swain S, Szabo A, Szarka I, Tabassam U, Taghavi S, Taillepied G, Takahashi J, Tambave G, Tang S, Tang Z, Tapia Takaki J, Tapus N, Tarzila M, Tauro A, Tejeda Muñoz G, Telesca A, Terlizzi L, Terrevoli C, Tersimonov G, Thakur S, Thomas D, Tieulent R, Tikhonov A, Timmins A, Tkacik M, Toia A, Topilskaya N, Toppi M, Torales-Acosta F, Tork T, Torres Ramos A, Trifiró A, Triolo A, Tripathy S, Tripathy T, Trogolo S, Trubnikov V, Trzaska W, Trzcinski T, Tumkin A, Turrisi R, Tveter T, Ullaland K, Uras A, Urioni M, Usai G, Vala M, Valle N, Vallero S, van Doremalen L, van Leeuwen M, Vande Vyvre P, Varga D, Varga Z, Varga-Kofarago M, Vasileiou M, Vasiliev A, Vázquez Doce O, Vechernin V, Velure A, Vercellin E, Vergara Limón S, Vermunt L, Vértesi R, Verweij M, Vickovic L, Vilakazi Z, Villalobos Baillie O, Vino G, Vinogradov A, Virgili T, Vislavicius V, Vodopyanov A, Volkel B, Völkl M, Voloshin K, Voloshin S, Volpe G, von Haller B, Vorobyev I, Vozniuk N, Vrláková J, Wagner B, Wang C, Wang D, Weber M, Weelden R, Wegrzynek A, Wenzel S, Wessels J, Weyhmiller S, Wiechula J, Wikne J, Wilk G, Wilkinson J, Willems G, Windelband B, Winn M, Witt W, Wright J, Wu W, Wu Y, Xu R, Yadav A, Yalcin S. First study of the two-body scattering involving charm hadrons. Int J Clin Exp Med 2022. [DOI: 10.1103/physrevd.106.052010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
59
|
Wallman-Jones A, Palser ER, Benzing V, Schmidt M. Acute physical-activity related increases in interoceptive ability are not enhanced with simultaneous interoceptive attention. Sci Rep 2022; 12:15054. [PMID: 36064565 PMCID: PMC9445090 DOI: 10.1038/s41598-022-19235-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2022] [Accepted: 08/25/2022] [Indexed: 01/23/2023] Open
Abstract
Interoception, the sense of the internal body, is proposed to support self-regulation, and consequently influence mental health. Researchers have therefore shown interest in improving the ability to accurately monitor internal signals (i.e., interoceptive accuracy, IAcc). Research suggests that cardiac IAcc is modifiable by both manipulations of interoceptive attention (guided attention towards the internal body), and interoceptive exposure (strategically inducing somatic signals e.g., via physical activity). Whilst successful in isolation, it is unclear whether a combined approach (i.e., directing attention towards the internal body when signals are more salient) could elicit greater benefits. In a 2 × 2 within-subject design, 48 healthy adults (Mage = 25.98 ± 4.73 years, 50% female) completed four 20-min conditions varying in both attentional focus (interoceptive vs exteroceptive) and physical activity (active vs rest), with cardiac IAcc measured immediately after. Results revealed a main effect for physical activity (p < 0.001), however, there was no effect for attentional focus (p = 0.397), and no interaction effect (p = 0.797). Differential analyses showed that a higher sporting background increased sensitivity to physical activity-related increases in cardiac IAcc (p = 0.031). Findings indicate that (irrespective of attentional focus) moderate-vigorous physical activity-based interventions have the potential to increase cardiac IAcc, with certain individuals potentially benefiting more.
Collapse
|
60
|
Albert J, Schühle P, Schmidt M, Schill L, Riisager A, Wasserscheid P. Development of robust indium‐based CO
2
hydrogenation catalysts for power‐to‐liquid concepts. CHEM-ING-TECH 2022. [DOI: 10.1002/cite.202255036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
61
|
Laakmann E, Riecke K, Neunhöffer T, Park-Simon TW, Weide R, Polasik A, Schmidt M, Puppe J, Fasching P, Hesse T, Decker T, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Mueller V, Witzel I. 269P Long-term survival of HER2-positive breast cancer patients with brain metastases: Subanalysis of the BMBC registry. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
62
|
Yoon S, Gadjimuradov F, Schmidt M, Wetzl J, Maier A. Fully automated machine learning-based selection of optimal bSSFP frequency offset for artifact reduction in cardiac MRI. Eur Heart J Cardiovasc Imaging 2022. [DOI: 10.1093/ehjci/jeac141.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Private company. Main funding source(s): Research Support from Siemens Healthineers GmbH.
Background
In bSSFP sequences commonly used for cardiac MRI, signal modulation (e.g. banding artifacts) due to B0 inhomogeneity is often observed, especially at higher field strengths. The spatial position of these artifacts can be shifted by a frequency offset to reduce artifacts in a region of interest (ROI), e.g. the heart. To this end, frequency scout (FS) scans are acquired to visually select the optimal frequency offset [1,2]. In this work, we propose a fully automated image-based system for selecting the optimal frequency offset on FS images based on machine learning.
Methods
The proposed prototype system consists of four main steps (Fig.1). First, a pre-trained deep-learning-based whole heart segmentation network is applied on a four chamber-view FS image to localize the ROI where artifacts should be reduced. Second, high frequency components within the ROI (for each frequency offset in the FS series) are extracted by successive processing of Fourier transformation, high-pass filtering, inverse Fourier transformation and subtraction over series. and N images with the lowest high-frequency content are selected. Third, an adaptive weighting map for each FS image is generated which penalizes signal deviations from a pixel-wise median that is calculated based on the selected images [3]. By averaging the maps and selecting the frame with maximum percentage, the optimal frequency offset is selected.
A total of 38 datasets, acquired on multiple clinical 3T MRI scanners (MAGNETOM Skyra, Vida, Prisma, Lumina; Siemens Healthcare, Erlangen, Germany), were used to evaluate the proposed system. All FS series were annotated manually and used to compare with the system output. The experts were allowed to select multiple possible optimal FS images within a FS series. In case of multiple annotations, the system output was labelled as correct when it selected one of the offsets chosen by the expert. Further, the generated weighting maps were visually evaluated.
Results
The proposed system achieved an accuracy of 92.1% compared to experts’ ground truth annotations. From the failed cases (n=3), the maximum difference was off by 2 frames. Based on the generated weighting maps, a reasonable decision on the selection of the optimal frequency offset is made. The algorithm successfully selects an FS image with minimized banding and flow artifacts within the ROI (Fig. 2a). Further, it reveals that the generated weighting map correctly suppress areas containing artifacts (Fig. 2b).
Conclusions
Initial results demonstrate the feasibility of the proposed system to automatically select the optimal frequency offset on FS scans. Therefore, it can improve the automation of a cardiac MRI workflow. An example of the result of each step
Collapse
|
63
|
Schmitz B, Gatsios D, Peña-Gil C, Juanatey J, Prieto D, Tsakanikas V, Scharnagl H, Habibovic M, Schmidt M, Kleber M, De Bruijn GJ, Malberg H, Mooren F, Widdershoven J, Maerz W, Fotiadis D, Kop W, Bosch J. Patient-centered cardiac rehabilitation by AI-powered lifestyle intervention – the timely approach. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.959] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
64
|
Frings VG, Jopp L, Srivastava M, Presser D, Goebeler M, Schmidt M. Stress signaling and STAT1 activation characterize the keratinocytic gene expression pattern in Hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2022; 36:2488-2498. [PMID: 35881108 DOI: 10.1111/jdv.18465] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2021] [Accepted: 07/11/2022] [Indexed: 11/26/2022]
Abstract
BACKGROUND The pathogenetic factors generating the innate immune signal necessary for T cell activation, initiation and chronification of Hidradenitis suppurativa (HS, also known as Acne inversa) are still poorly understood. Emerging evidence suggests that a defective keratinocyte function critically contributes to HS disease development and progression. OBJECTIVES To elucidate the role of keratinocytes in HS lesion formation, we compared the transcriptomes of lesional and perilesional epidermis isolated from HS patients by RNA sequencing (RNA Seq). METHODS Pairwise-matched lesional and perilesional HS skin samples of five different donors were obtained and epidermal keratinocytes freshly isolated and processed for RNA extraction and RNA seq. Lesionally regulated genes were analyzed by large scale promotor analysis and functional annotation clustering to identify epidermally overrepresented transcription factor binding sites and functionally related gene groups. Results were experimentally validated with independent epidermal isolates of patient-matched lesional and perilesional HS skin employing qRT-PCR, cell culture, immunoblot, and immunostaining. RESULTS We show that HS is characterized by a strong epidermal stress state evident by a significant overrepresentation of an AP-1-driven gene signature and a substantial activation of the stress-activated cJun N-terminal kinase (JNK) pathway in lesional epidermis. Additionally, our data reveal a strong induction of STAT1 activation in lesional HS epidermis that likely results from IFNγ production and triggered expression of key inflammatory genes coordinating innate immune activation and the adaptive T cell response in HS. CONCLUSIONS Our data implicate a key role of stress signaling and JAK/STAT1 activation in disease progression of HS and suggest interference with JAK/STAT1 signaling as a potentially promising therapeutic approach for HS.
Collapse
|
65
|
Acharya S, Adamová D, Adler A, Aglieri Rinella G, Agnello M, Agrawal N, Ahammed Z, Ahmad S, Ahn SU, Ahuja I, Akbar Z, Akindinov A, Al-Turany M, Alam SN, Aleksandrov D, Alessandro B, Alfanda HM, Alfaro Molina R, Ali B, Ali Y, Alici A, Alizadehvandchali N, Alkin A, Alme J, Alt T, Altenkamper L, Altsybeev I, Anaam MN, Andrei C, Andreou D, Andronic A, Angeletti M, Anguelov V, Antinori F, Antonioli P, Anuj C, Apadula N, Aphecetche L, Appelshäuser H, Arcelli S, Arnaldi R, Arsene IC, Arslandok M, Augustinus A, Averbeck R, Aziz S, Azmi MD, Badalà A, Baek YW, Bai X, Bailhache R, Bailung Y, Bala R, Balbino A, Baldisseri A, Balis B, Ball M, Banerjee D, Barbera R, Barioglio L, Barlou M, Barnaföldi GG, Barnby LS, Barret V, Bartels C, Barth K, Bartsch E, Baruffaldi F, Bastid N, Basu S, Batigne G, Batyunya B, Bauri D, Bazo Alba JL, Bearden IG, Beattie C, Belikov I, Bell Hechavarria ADC, Bellini F, Bellwied R, Belokurova S, Belyaev V, Bencedi G, Beole S, Bercuci A, Berdnikov Y, Berdnikova A, Bergmann L, Besoiu MG, Betev L, Bhaduri PP, Bhasin A, Bhat IR, Bhat MA, Bhattacharjee B, Bhattacharya P, Bianchi L, Bianchi N, Bielčík J, Bielčíková J, Biernat J, Bilandzic A, Biro G, Biswas S, Blair JT, Blau D, Blidaru MB, Blume C, Boca G, Bock F, Bogdanov A, Boi S, Bok J, Boldizsár L, Bolozdynya A, Bombara M, Bond PM, Bonomi G, Borel H, Borissov A, Bossi H, Botta E, Bratrud L, Braun-Munzinger P, Bregant M, Broz M, Bruno GE, Buckland MD, Budnikov D, Buesching H, Bufalino S, Bugnon O, Buhler P, Buthelezi Z, Butt JB, Bysiak SA, Cai M, Caines H, Caliva A, Calvo Villar E, Camacho JMM, Camacho RS, Camerini P, Canedo FDM, Carnesecchi F, Caron R, Castillo Castellanos J, Casula EAR, Catalano F, Ceballos Sanchez C, Chakraborty P, Chandra S, Chapeland S, Chartier M, Chattopadhyay S, Chattopadhyay S, Chauvin A, Chavez TG, Cheng T, Cheshkov C, Cheynis B, Chibante Barroso V, Chinellato DD, Cho S, Chochula P, Christakoglou P, Christensen CH, Christiansen P, Chujo T, Cicalo C, Cifarelli L, Cindolo F, Ciupek MR, Clai G, Cleymans J, Colamaria F, Colburn JS, Colella D, Collu A, Colocci M, Concas M, Conesa Balbastre G, Conesa Del Valle Z, Contin G, Contreras JG, Coquet ML, Cormier TM, Cortese P, Cosentino MR, Costa F, Costanza S, Crochet P, Cruz-Torres R, Cuautle E, Cui P, Cunqueiro L, Dainese A, Danisch MC, Danu A, Das I, Das P, Das P, Das S, Dash S, De S, De Caro A, de Cataldo G, De Cilladi L, de Cuveland J, De Falco A, De Gruttola D, De Marco N, De Martin C, De Pasquale S, Deb S, Degenhardt HF, Deja KR, Dello Stritto L, Delsanto S, Deng W, Dhankher P, Di Bari D, Di Mauro A, Diaz RA, Dietel T, Ding Y, Divià R, Dixit DU, Djuvsland Ø, Dmitrieva U, Do J, Dobrin A, Dönigus B, Dordic O, Dubey AK, Dubla A, Dudi S, Dukhishyam M, Dupieux P, Dzalaiova N, Eder TM, Ehlers RJ, Eikeland VN, Eisenhut F, Elia D, Erazmus B, Ercolessi F, Erhardt F, Erokhin A, Ersdal MR, Espagnon B, Eulisse G, Evans D, Evdokimov S, Fabbietti L, Faggin M, Faivre J, Fan F, Fantoni A, Fasel M, Fecchio P, Feliciello A, Feofilov G, Fernández Téllez A, Ferrero A, Ferretti A, Feuillard VJG, Figiel J, Filchagin S, Finogeev D, Fionda FM, Fiorenza G, Flor F, Flores AN, Foertsch S, Foka P, Fokin S, Fragiacomo E, Frajna E, Fuchs U, Funicello N, Furget C, Furs A, Gaardhøje JJ, Gagliardi M, Gago AM, Gal A, Galvan CD, Ganoti P, Garabatos C, Garcia JRA, Garcia-Solis E, Garg K, Gargiulo C, Garibli A, Garner K, Gasik P, Gauger EF, Gautam A, Gay Ducati MB, Germain M, Ghosh P, Ghosh SK, Giacalone M, Gianotti P, Giubellino P, Giubilato P, Glaenzer AMC, Glässel P, Goh DJQ, Gonzalez V, González-Trueba LH, Gorbunov S, Gorgon M, Görlich L, Gotovac S, Grabski V, Graczykowski LK, Greiner L, Grelli A, Grigoras C, Grigoriev V, Grigoryan A, Grigoryan S, Groettvik OS, Grosa F, Grosse-Oetringhaus JF, Grosso R, Guardiano GG, Guernane R, Guilbaud M, Gulbrandsen K, Gunji T, Guo W, Gupta A, Gupta R, Guzman SP, Gyulai L, Habib MK, Hadjidakis C, Halimoglu G, Hamagaki H, Hamar G, Hamid M, Hannigan R, Haque MR, Harlenderova A, Harris JW, Harton A, Hasenbichler JA, Hassan H, Hatzifotiadou D, Hauer P, Havener LB, Hayashi S, Heckel ST, Hellbär E, Helstrup H, Herman T, Hernandez EG, Herrera Corral G, Herrmann F, Hetland KF, Hillemanns H, Hills C, Hippolyte B, Hofman B, Hohlweger B, Honermann J, Hong GH, Horak D, Hornung S, Horzyk A, Hosokawa R, Hou Y, Hristov P, Hughes C, Huhn P, Humanic TJ, Hushnud H, Husova LA, Hutson A, Hutter D, Iddon JP, Ilkaev R, Ilyas H, Inaba M, Innocenti GM, Ippolitov M, Isakov A, Islam MS, Ivanov M, Ivanov V, Izucheev V, Jablonski M, Jacak B, Jacazio N, Jacobs PM, Jadlovska S, Jadlovsky J, Jaelani S, Jahnke C, Jakubowska MJ, Jalotra A, Janik MA, Janson T, Jercic M, Jevons O, Jimenez AAP, Jonas F, Jones PG, Jowett JM, Jung J, Jung M, Junique A, Jusko A, Kaewjai J, Kalinak P, Kalweit A, Kaplin V, Kar S, Karasu Uysal A, Karatovic D, Karavichev O, Karavicheva T, Karczmarczyk P, Karpechev E, Kazantsev A, Kebschull U, Keidel R, Keijdener DLD, Keil M, Ketzer B, Khabanova Z, Khan AM, Khan S, Khanzadeev A, Kharlov Y, Khatun A, Khuntia A, Kileng B, Kim B, Kim C, Kim DJ, Kim EJ, Kim J, Kim JS, Kim J, Kim J, Kim J, Kim M, Kim S, Kim T, Kirsch S, Kisel I, Kiselev S, Kisiel A, Kitowski JP, Klay JL, Klein J, Klein S, Klein-Bösing C, Kleiner M, Klemenz T, Kluge A, Knospe AG, Kobdaj C, Köhler MK, Kollegger T, Kondratyev A, Kondratyeva N, Kondratyuk E, Konig J, Konigstorfer SA, Konopka PJ, Kornakov G, Koryciak SD, Koska L, Kotliarov A, Kovalenko O, Kovalenko V, Kowalski M, Králik I, Kravčáková A, Kreis L, Krivda M, Krizek F, Krizkova Gajdosova K, Kroesen M, Krüger M, Kryshen E, Krzewicki M, Kučera V, Kuhn C, Kuijer PG, Kumaoka T, Kumar D, Kumar L, Kumar N, Kundu S, Kurashvili P, Kurepin A, Kurepin AB, Kuryakin A, Kushpil S, Kvapil J, Kweon MJ, Kwon JY, Kwon Y, La Pointe SL, La Rocca P, Lai YS, Lakrathok A, Lamanna M, Langoy R, Lapidus K, Larionov P, Laudi E, Lautner L, Lavicka R, Lazareva T, Lea R, Lehrbach J, Lemmon RC, León Monzón I, Lesser ED, Lettrich M, Lévai P, Li X, Li XL, Lien J, Lietava R, Lim B, Lim SH, Lindenstruth V, Lindner A, Lippmann C, Liu A, Liu DH, Liu J, Lofnes IM, Loginov V, Loizides C, Loncar P, Lopez JA, Lopez X, López Torres E, Luhder JR, Lunardon M, Luparello G, Ma YG, Maevskaya A, Mager M, Mahmoud T, Maire A, Malaev M, Malik NM, Malik QW, Malinina L, Mal'Kevich D, Mallick N, Malzacher P, Mandaglio G, Manko V, Manso F, Manzari V, Mao Y, Mareš J, Margagliotti GV, Margotti A, Marín A, Markert C, Marquard M, Martin NA, Martinengo P, Martinez JL, Martínez MI, Martínez García G, Masciocchi S, Masera M, Masoni A, Massacrier L, Mastroserio A, Mathis AM, Matonoha O, Matuoka PFT, Matyja A, Mayer C, Mazuecos AL, Mazzaschi F, Mazzilli M, Mazzoni MA, Mdhluli JE, Mechler AF, Meddi F, Melikyan Y, Menchaca-Rocha A, Meninno E, Menon AS, Meres M, Mhlanga S, Miake Y, Micheletti L, Migliorin LC, Mihaylov DL, Mikhaylov K, Mishra AN, Miśkowiec D, Modak A, Mohanty AP, Mohanty B, Mohisin Khan M, Molander MA, Moravcova Z, Mordasini C, Moreira De Godoy DA, Moreno LAP, Morozov I, Morsch A, Mrnjavac T, Muccifora V, Mudnic E, Mühlheim D, Muhuri S, Mulligan JD, Mulliri A, Munhoz MG, Munzer RH, Murakami H, Murray S, Musa L, Musinsky J, Myrcha JW, Naik B, Nair R, Nandi BK, Nania R, Nappi E, Nassirpour AF, Nath A, Nattrass C, Neagu A, Nellen L, Nesbo SV, Neskovic G, Nesterov D, Nielsen BS, Nikolaev S, Nikulin S, Nikulin V, Noferini F, Noh S, Nomokonov P, Norman J, Novitzky N, Nowakowski P, Nyanin A, Nystrand J, Ogino M, Ohlson A, Okorokov VA, Oleniacz J, Oliveira Da Silva AC, Oliver MH, Onnerstad A, Oppedisano C, Ortiz Velasquez A, Osako T, Oskarsson A, Otwinowski J, Oya M, Oyama K, Pachmayer Y, Padhan S, Pagano D, Paić G, Palasciano A, Pan J, Panebianco S, Pareek P, Park J, Parkkila JE, Pathak SP, Patra RN, Paul B, Pei H, Peitzmann T, Peng X, Pereira LG, Pereira Da Costa H, Peresunko D, Perez GM, Perrin S, Pestov Y, Petráček V, Petrovici M, Pezzi RP, Piano S, Pikna M, Pillot P, Pinazza O, Pinsky L, Pinto C, Pisano S, Płoskoń M, Planinic M, Pliquett F, Poghosyan MG, Polichtchouk B, Politano S, Poljak N, Pop A, Porteboeuf-Houssais S, Porter J, Pozdniakov V, Prasad SK, Preghenella R, Prino F, Pruneau CA, Pshenichnov I, Puccio M, Qiu S, Quaglia L, Quishpe RE, Ragoni S, Rakotozafindrabe A, Ramello L, Rami F, Ramirez SAR, Ramos AGT, Rancien TA, Raniwala R, Raniwala S, Räsänen SS, Rath R, Ravasenga I, Read KF, Redelbach AR, Redlich K, Rehman A, Reichelt P, Reidt F, Reme-Ness HA, Renfordt R, Rescakova Z, Reygers K, Riabov A, Riabov V, Richert T, Richter M, Riegler W, Riggi F, Ristea C, Rodríguez Cahuantzi M, Røed K, Rogalev R, Rogochaya E, Rogoschinski TS, Rohr D, Röhrich D, Rojas PF, Rokita PS, Ronchetti F, Rosano A, Rosas ED, Rossi A, Rotondi A, Roy A, Roy P, Roy S, Rubini N, Rueda OV, Rui R, Rumyantsev B, Russek PG, Rustamov A, Ryabinkin E, Ryabov Y, Rybicki A, Rytkonen H, Rzesa W, Saarimaki OAM, Sadek R, Sadovsky S, Saetre J, Šafařík K, Saha SK, Saha S, Sahoo B, Sahoo P, Sahoo R, Sahoo S, Sahu D, Sahu PK, Saini J, Sakai S, Sambyal S, Samsonov V, Sarkar D, Sarkar N, Sarma P, Sarti VM, Sas MHP, Schambach J, Scheid HS, Schiaua C, Schicker R, Schmah A, Schmidt C, Schmidt HR, Schmidt MO, Schmidt M, Schmidt NV, Schmier AR, Schotter R, Schukraft J, Schutz Y, Schwarz K, Schweda K, Scioli G, Scomparin E, Seger JE, Sekiguchi Y, Sekihata D, Selyuzhenkov I, Senyukov S, Seo JJ, Serebryakov D, Šerkšnytė L, Sevcenco A, Shaba TJ, Shabanov A, Shabetai A, Shahoyan R, Shaikh W, Shangaraev A, Sharma A, Sharma H, Sharma M, Sharma N, Sharma S, Sharma U, Sheibani O, Shigaki K, Shimomura M, Shirinkin S, Shou Q, Sibiriak Y, Siddhanta S, Siemiarczuk T, Silva TF, Silvermyr D, Simantathammakul T, Simonetti G, Singh B, Singh R, Singh R, Singh R, Singh VK, Singhal V, Sinha T, Sitar B, Sitta M, Skaali TB, Skorodumovs G, Slupecki M, Smirnov N, Snellings RJM, Soncco C, Song J, Songmoolnak A, Soramel F, Sorensen S, Sputowska I, Stachel J, Stan I, Steffanic PJ, Stiefelmaier SF, Stocco D, Storehaug I, Storetvedt MM, Stylianidis CP, Suaide AAP, Sugitate T, Suire C, Sukhanov M, Suljic M, Sultanov R, Šumbera M, Sumberia V, Sumowidagdo S, Swain S, Szabo A, Szarka I, Tabassam U, Taghavi SF, Taillepied G, Takahashi J, Tambave GJ, Tang S, Tang Z, Tarhini M, Tarzila MG, Tauro A, Tejeda Muñoz G, Telesca A, Terlizzi L, Terrevoli C, Tersimonov G, Thakur S, Thomas D, Tieulent R, Tikhonov A, Timmins AR, Tkacik M, Toia A, Topilskaya N, Toppi M, Torales-Acosta F, Tork T, Torres SR, Trifiró A, Tripathy S, Tripathy T, Trogolo S, Trombetta G, Trubnikov V, Trzaska WH, Trzcinski TP, Trzeciak BA, Tumkin A, Turrisi R, Tveter TS, Ullaland K, Uras A, Urioni M, Usai GL, Vala M, Valle N, Vallero S, van der Kolk N, van Doremalen LVR, van Leeuwen M, Vande Vyvre P, Varga D, Varga Z, Varga-Kofarago M, Vargas A, Vasileiou M, Vasiliev A, Vázquez Doce O, Vechernin V, Vercellin E, Vergara Limón S, Vermunt L, Vértesi R, Verweij M, Vickovic L, Vilakazi Z, Villalobos Baillie O, Vino G, Vinogradov A, Virgili T, Vislavicius V, Vodopyanov A, Volkel B, Völkl MA, Voloshin K, Voloshin SA, Volpe G, von Haller B, Vorobyev I, Voscek D, Vozniuk N, Vrláková J, Wagner B, Wang C, Wang D, Weber M, Weelden RJGV, Wegrzynek A, Wenzel SC, Wessels JP, Wiechula J, Wikne J, Wilk G, Wilkinson J, Willems GA, Windelband B, Winn M, Witt WE, Wright JR, Wu W, Wu Y, Xu R, Yadav AK, Yalcin S, Yamaguchi Y, Yamakawa K, Yang S, Yano S, Yin Z, Yokoyama H, Yoo IK, Yoon JH, Yuan S, Yuncu A, Zaccolo V, Zampolli C, Zanoli HJC, Zardoshti N, Zarochentsev A, Závada P, Zaviyalov N, Zhalov M, Zhang B, Zhang S, Zhang X, Zhang Y, Zherebchevskii V, Zhi Y, Zhigareva N, Zhou D, Zhou Y, Zhu J, Zhu Y, Zichichi A, Zinovjev G, Zurlo N. Hypertriton Production in p-Pb Collisions at sqrt[s_{NN}]=5.02 TeV. PHYSICAL REVIEW LETTERS 2022; 128:252003. [PMID: 35802430 DOI: 10.1103/physrevlett.128.252003] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Revised: 01/28/2022] [Accepted: 06/03/2022] [Indexed: 06/15/2023]
Abstract
The study of nuclei and antinuclei production has proven to be a powerful tool to investigate the formation mechanism of loosely bound states in high-energy hadronic collisions. The first measurement of the production of _{Λ}^{3}H in p-Pb collisions at sqrt[s_{NN}]=5.02 TeV is presented in this Letter. Its production yield measured in the rapidity interval -1<y<0 for the 40% highest-multiplicity p-Pb collisions is dN/dy=[6.3±1.8(stat)±1.2(syst)]×10^{-7}. The measurement is compared with the expectations of statistical hadronization and coalescence models, which describe the nucleosynthesis in hadronic collisions. These two models predict very different yields of the hypertriton in charged particle multiplicity environments relevant to small collision systems such as p-Pb, and therefore the measurement of dN/dy is crucial to distinguish between them. The precision of this measurement leads to the exclusion with a significance larger than 6.9σ of some configurations of the statistical hadronization model, thus constraining the theory behind the production of loosely bound states at hadron colliders.
Collapse
|
66
|
Mudunkotuwe J, Schmidt M, Khan A, Sahlsberg T. Taking back control of the Data. Developing an all in one System to monitor training post quality and provide trainer feedback. Eur Psychiatry 2022. [PMCID: PMC9567376 DOI: 10.1192/j.eurpsy.2022.2199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Introduction We will present experience developing a system for monitoring training placements in psychiatry and community paediatrics, and how this was expanded to provide an automated anonymised MSF for trainers for annual appraisal and will identify trainers in need of additional support and other post/training programme issues. The session will be of interest to educators and medical education leads with practical tips and lessons learnt over the last 8 years since the system was first developed. Objectives The system was also used to identify trainers in need of additional support and other post/training programme issues. Methods We used an electronic system to gain the infromation as stated in the introduction. Results Over the last 8 years we have collected data using this system. the results for our trust will be displayed annoymously but the system is the ficus of this presenation. Conclusions The advantages of the system are that it runs throughout the year (so covers each post and placement), has high trainee response rates, has no selection bias (compared with some other MSF systems) and the results are embedded within local quality systems and individual consultant appraisals. The data that the system collects can help provide robust evidence when investigating concerns that might only arise periodically (for example through the annual GMC trainee survey in the UK). We believe that this system will be applicable for doctors providing training in other countries and empowers the improvement of psychiatric training for the profession. Disclosure No significant relationships.
Collapse
|
67
|
Pineton De Chambrun M, Charuel J, Dorgham K, Quentric P, Kerneis M, Lebreton G, Miyara M, Schmidt M, Luyt C, Melki I, Moyon Q, Lifermann F, Mathian A, Gorochov G, Amoura Z, Combes A, Hekimian G. Myocardites fulminantes associées aux auto-anticorps Anti-ARN-polymérases III. Rev Med Interne 2022. [DOI: 10.1016/j.revmed.2022.03.315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
68
|
Logemann A, Reininghaus M, Schmidt M, Ebeling A, Zimmermann T, Wolschke H, Friedrich J, Brockmeyer B, Pröfrock D, Witt G. Assessing the chemical anthropocene - Development of the legacy pollution fingerprint in the North Sea during the last century. ENVIRONMENTAL POLLUTION (BARKING, ESSEX : 1987) 2022; 302:119040. [PMID: 35202763 DOI: 10.1016/j.envpol.2022.119040] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/01/2021] [Revised: 02/15/2022] [Accepted: 02/18/2022] [Indexed: 06/14/2023]
Abstract
The North Sea and its coastal zones are heavily impacted by anthropogenic activities, which has resulted in significant chemical pollution ever since the beginning of the industrialization in Europe during the 19th century. In order to assess the chemical Anthropocene, natural archives, such as sediment cores, can serve as a valuable data source to reconstruct historical emission trends and to verify the effectiveness of changing environmental legislation. In this study, we investigated 90 contaminants covering inorganic and organic pollutant groups analyzed in a set of sediment cores taken in the North Seas' main sedimentation area (Skagerrak). We thereby develop a chemical pollution fingerprint that records the constant input of pollutants over time and illustrates their continued great relevance for the present. Additionally, samples were radiometrically dated and PAH and PCB levels in porewater were determined using equilibrium passive sampling. Furthermore, we elucidated the origin of lead (Pb) contamination utilizing non-traditional stable isotopic analysis. Our results reveal three main findings: 1. for all organic contaminant groups covered (PAHs, OCPs, PCBs, PBDEs and PFASs) as well as the elements lead (Pb) and titanium (Ti), determined concentrations decreased towards more recent deposited sediment. These decreasing trends could be linked to the time of introductions of restrictions and bans and therefor our results confirm, amongst possible other factors, the effectiveness of environmental legislation by revealing a successive change in contamination levels over the decades. 2. concentration trends for ΣPAH and ΣPCB measured in porewater correspond well with the ones found in sediment which suggests that this method can be a useful expansion to traditional bulk sediment analysis to determine the biologically available pollutant fraction. 3. Arsenic (As) concentrations were higher in younger sediment layers, potentially caused by emissions of corroded warfare material disposed in the study area after WW II.
Collapse
|
69
|
Laakmann E, Witzel I, Neunhöffer T, Park-Simon TW, Weide R, Riecke K, Polasik A, Schmidt M, Puppe J, Mundhenke C, Lübbe K, Hesse T, Thill M, Zahm DM, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Müller V. Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry. ESMO Open 2022; 7:100495. [PMID: 35653983 PMCID: PMC9271494 DOI: 10.1016/j.esmoop.2022.100495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2022] [Revised: 04/13/2022] [Accepted: 04/14/2022] [Indexed: 11/24/2022] Open
Abstract
Background Up to 40% of patients with metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer develop brain metastases (BMs). Understanding of clinical features of these patients with HER2-positive breast cancer and BMs is vital. Patients and methods A total of 2948 patients from the Brain Metastases in Breast Cancer registry were available for this analysis, of whom 1311 had primary tumors with the HER2-positive subtype. Results Patients with HER2-positive breast cancer and BMs were—when compared with HER2-negative patients—slightly younger at the time of breast cancer and BM diagnosis, had a higher pathologic complete response rate after neoadjuvant chemotherapy and a higher tumor grade. Furthermore, extracranial metastases at the time of BM diagnosis were less common in HER2-positive patients, when compared with HER2-negative patients. HER2-positive patients had more often BMs in the posterior fossa, but less commonly leptomeningeal metastases. The median overall survival (OS) in all HER2-positive patients was 13.2 months (95% confidence interval 11.4-14.4). The following factors were associated with shorter OS (multivariate analysis): older age at BM diagnosis [≥60 versus <60 years: hazard ratio (HR) 1.63, P < 0.001], lower Eastern Cooperative Oncology Group status (2-4 versus 0-1: HR 1.59, P < 0.001), higher number of BMs (2-3 versus 1: HR 1.30, P = 0.082; ≥4 versus 1: HR 1.51, P = 0.004; global P = 0.015), BMs in the fossa anterior (HR 1.71, P < 0.001), leptomeningeal metastases (HR 1.63, P = 0.012), symptomatic BMs at diagnosis (HR 1.35, P = 0.033) and extracranial metastases at diagnosis of BMs (HR 1.43, P = 0.020). The application of targeted therapy after the BM diagnosis (HR 0.62, P < 0.001) was associated with longer OS. HER2-positive/hormone receptor-positive patients showed longer OS than HER2-positive/hormone receptor-negative patients (median 14.3 versus 10.9 months; HR 0.86, P = 0.03), but no differences in progression-free survival were seen between both groups. Conclusions We identified factors associated with the prognosis of HER2-positive patients with BMs. Further research is needed to understand the factors determining the longer survival of HER2-positive/hormone receptor-positive patients. Patients with HER2-positive BMs from breast cancer have the best prognosis compared with other tumor subtypes. Among HER2-positive patients, hormone receptor-positive patients have the longest survival. HER2-targeted therapy is significantly associated with a better prognosis in patients with BMs. On average, two HER2-targeted therapy lines were administered prior to the development of BMs. New compounds are urgently needed to improve the outcome of this subgroup of patients.
Collapse
|
70
|
Gentile P, Merlo M, Peretto G, Ammirati E, Sala S, Della Bella P, Aquaro G, Imazio M, Potena L, Campodonico J, Foà A, Raafs A, Hazebroek M, Brambatti M, Cercek A, Nucifora G, Shrivastava S, Huang F, Schmidt M, Muser D, Van De Heyning C, Van Craenenbroeck E, Aoki T, Sugimura K, Shimokawa H, Cannatà A, Artico J, Porcari A, Colopi M, Bussani R, Barbati G, Garascia A, Cipriani M, Agostoni P, Pereira N, Heymans S, Adler E, Camici P, Frigerio M, Sinagra G. C65 POST–DISCHARGE ARRHYTHMIC RISK STRATIFICATION OF PATIENTS WITH ACUTE MYOCARDITIS AND LIFE–THREATENING VENTRICULAR TACHYARRHYTHMIAS. Eur Heart J Suppl 2022. [DOI: 10.1093/eurheartj/suac011.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
Aims
The outcomes of patients presenting with acute myocarditis and life–threatening ventricular arrhythmias (LT–VA) are unclear. The aim of this study was to assess the incidence and predictors of recurrent major arrhythmic events (MAEs) after hospital discharge in this patient population.
Methods and Results
We retrospectively analysed 156 patients (median age 44 years; 77% male) discharged with a diagnosis of acute myocarditis and LT–VA from 16 hospitals worldwide. Diagnosis of myocarditis was based on histology or the combination of increased markers of cardiac injury and cardiac magnetic resonance (CMR) Lake Louise criteria. MAEs were defined as the relapse, after discharge, of sudden cardiac death or successfully defibrillated ventricular fibrillation, or sustained ventricular tachycardia (sVT) requiring implantable cardioverter–defibrillator therapy or synchronized external cardioversion. Median follow–up was 23months [first to third quartile (Q1–Q3) 7–60]. Fifty–eight (37.2%) patients experienced MAEs after discharge, at a median of 8 months (Q1–Q3 2.5–24.0 months; 60.3% of MAEs within the first year). At multivariable Cox analysis, variables independently associated with MAEs were presentation with sVT [hazard ratio (HR) 2.90, 95% confidence interval (CI) 1.38–6.11]; late gadolinium enhancement involving ≥2 myocardial segments (HR 4.51, 95% CI 2.39–8.53), and absence of positive short–tau inversion recovery (STIR) (HR 2.59, 95% CI 1.40–4.79) at first CMR.
Conclusions
In this international multicentre study, patients discharged free from HTx or LVAD after an acute myocarditis complicated by LT–VA had a recurrence of MAEs during follow–up of 37.2%, after a median time of 8 months. Initial CMR pattern and sVT at presentation stratify the risk of arrhythmia recurrence.
Collapse
|
71
|
Riecke K, Laakmann E, Neunhöffer T, Park-Simon TW, Weide R, Schmidt M, Polasik A, Puppe J, Mundhenke C, Lübbe K, Hesse T, Thill M, Zahm DM, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Müller V, Witzel I. 170P Long-term survival of breast cancer patients with brain metastases: Subanalysis of the BMBC registry. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.03.189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
72
|
Acharya S, Adamová D, Adler A, Aglieri Rinella G, Agnello M, Agrawal N, Ahammed Z, Ahmad S, Ahn SU, Ahuja I, Akbar Z, Akindinov A, Al-Turany M, Alam SN, Aleksandrov D, Alessandro B, Alfanda HM, Alfaro Molina R, Ali B, Ali Y, Alici A, Alizadehvandchali N, Alkin A, Alme J, Alt T, Altenkamper L, Altsybeev I, Anaam MN, Andrei C, Andreou D, Andronic A, Angeletti M, Anguelov V, Antinori F, Antonioli P, Anuj C, Apadula N, Aphecetche L, Appelshäuser H, Arcelli S, Arnaldi R, Arsene IC, Arslandok M, Augustinus A, Averbeck R, Aziz S, Azmi MD, Badalà A, Baek YW, Bai X, Bailhache R, Bailung Y, Bala R, Balbino A, Baldisseri A, Balis B, Ball M, Banerjee D, Barbera R, Barioglio L, Barlou M, Barnaföldi GG, Barnby LS, Barret V, Bartels C, Barth K, Bartsch E, Baruffaldi F, Bastid N, Basu S, Batigne G, Batyunya B, Bauri D, Bazo Alba JL, Bearden IG, Beattie C, Belikov I, Bell Hechavarria ADC, Bellini F, Bellwied R, Belokurova S, Belyaev V, Bencedi G, Beole S, Bercuci A, Berdnikov Y, Berdnikova A, Bergmann L, Besoiu MG, Betev L, Bhaduri PP, Bhasin A, Bhat IR, Bhat MA, Bhattacharjee B, Bhattacharya P, Bianchi L, Bianchi N, Bielčík J, Bielčíková J, Biernat J, Bilandzic A, Biro G, Biswas S, Blair JT, Blau D, Blidaru MB, Blume C, Boca G, Bock F, Bogdanov A, Boi S, Bok J, Boldizsár L, Bolozdynya A, Bombara M, Bond PM, Bonomi G, Borel H, Borissov A, Bossi H, Botta E, Bratrud L, Braun-Munzinger P, Bregant M, Broz M, Bruno GE, Buckland MD, Budnikov D, Buesching H, Bufalino S, Bugnon O, Buhler P, Buthelezi Z, Butt JB, Bysiak SA, Cai M, Caines H, Caliva A, Calvo Villar E, Camacho JMM, Camacho RS, Camerini P, Canedo FDM, Carnesecchi F, Caron R, Castillo Castellanos J, Casula EAR, Catalano F, Ceballos Sanchez C, Chakraborty P, Chandra S, Chapeland S, Chartier M, Chattopadhyay S, Chattopadhyay S, Chauvin A, Chavez TG, Cheng T, Cheshkov C, Cheynis B, Chibante Barroso V, Chinellato DD, Cho S, Chochula P, Christakoglou P, Christensen CH, Christiansen P, Chujo T, Cicalo C, Cifarelli L, Cindolo F, Ciupek MR, Clai G, Cleymans J, Colamaria F, Colburn JS, Colella D, Collu A, Colocci M, Concas M, Conesa Balbastre G, Conesa Del Valle Z, Contin G, Contreras JG, Coquet ML, Cormier TM, Cortese P, Cosentino MR, Costa F, Costanza S, Crochet P, Cruz-Torres R, Cuautle E, Cui P, Cunqueiro L, Dainese A, Danisch MC, Danu A, Das I, Das P, Das P, Das S, Dash S, De S, De Caro A, de Cataldo G, De Cilladi L, de Cuveland J, De Falco A, De Gruttola D, De Marco N, De Martin C, De Pasquale S, Deb S, Degenhardt HF, Deja KR, Dello Stritto L, Delsanto S, Deng W, Dhankher P, Di Bari D, Di Mauro A, Diaz RA, Dietel T, Ding Y, Divià R, Dixit DU, Djuvsland Ø, Dmitrieva U, Do J, Dobrin A, Dönigus B, Dordic O, Dubey AK, Dubla A, Dudi S, Dukhishyam M, Dupieux P, Dzalaiova N, Eder TM, Ehlers RJ, Eikeland VN, Eisenhut F, Elia D, Erazmus B, Ercolessi F, Erhardt F, Erokhin A, Ersdal MR, Espagnon B, Eulisse G, Evans D, Evdokimov S, Fabbietti L, Faggin M, Faivre J, Fan F, Fantoni A, Fasel M, Fecchio P, Feliciello A, Feofilov G, Fernández Téllez A, Ferrero A, Ferretti A, Feuillard VJG, Figiel J, Filchagin S, Finogeev D, Fionda FM, Fiorenza G, Flor F, Flores AN, Foertsch S, Foka P, Fokin S, Fragiacomo E, Frajna E, Fuchs U, Funicello N, Furget C, Furs A, Gaardhøje JJ, Gagliardi M, Gago AM, Gal A, Galvan CD, Ganoti P, Garabatos C, Garcia JRA, Garcia-Solis E, Garg K, Gargiulo C, Garibli A, Garner K, Gasik P, Gauger EF, Gautam A, Gay Ducati MB, Germain M, Ghosh P, Ghosh SK, Giacalone M, Gianotti P, Giubellino P, Giubilato P, Glaenzer AMC, Glässel P, Goh DJQ, Gonzalez V, González-Trueba LH, Gorbunov S, Gorgon M, Görlich L, Gotovac S, Grabski V, Graczykowski LK, Greiner L, Grelli A, Grigoras C, Grigoriev V, Grigoryan S, Groettvik OS, Grosa F, Grosse-Oetringhaus JF, Grosso R, Guardiano GG, Guernane R, Guilbaud M, Gulbrandsen K, Gunji T, Guo W, Gupta A, Gupta R, Guzman SP, Gyulai L, Habib MK, Hadjidakis C, Halimoglu G, Hamagaki H, Hamar G, Hamid M, Hannigan R, Haque MR, Harlenderova A, Harris JW, Harton A, Hasenbichler JA, Hassan H, Hatzifotiadou D, Hauer P, Havener LB, Hayashi S, Heckel ST, Hellbär E, Helstrup H, Herman T, Hernandez EG, Herrera Corral G, Herrmann F, Hetland KF, Hillemanns H, Hills C, Hippolyte B, Hofman B, Hohlweger B, Honermann J, Hong GH, Horak D, Hornung S, Horzyk A, Hosokawa R, Hou Y, Hristov P, Hughes C, Huhn P, Humanic TJ, Hushnud H, Husova LA, Hutson A, Hutter D, Iddon JP, Ilkaev R, Ilyas H, Inaba M, Innocenti GM, Ippolitov M, Isakov A, Islam MS, Ivanov M, Ivanov V, Izucheev V, Jablonski M, Jacak B, Jacazio N, Jacobs PM, Jadlovska S, Jadlovsky J, Jaelani S, Jahnke C, Jakubowska MJ, Jalotra A, Janik MA, Janson T, Jercic M, Jevons O, Jimenez AAP, Jonas F, Jones PG, Jowett JM, Jung J, Jung M, Junique A, Jusko A, Kaewjai J, Kalinak P, Kalweit A, Kaplin V, Kar S, Karasu Uysal A, Karatovic D, Karavichev O, Karavicheva T, Karczmarczyk P, Karpechev E, Kazantsev A, Kebschull U, Keidel R, Keijdener DLD, Keil M, Ketzer B, Khabanova Z, Khan AM, Khan S, Khanzadeev A, Kharlov Y, Khatun A, Khuntia A, Kileng B, Kim B, Kim C, Kim DJ, Kim EJ, Kim J, Kim JS, Kim J, Kim J, Kim J, Kim M, Kim S, Kim T, Kirsch S, Kisel I, Kiselev S, Kisiel A, Kitowski JP, Klay JL, Klein J, Klein S, Klein-Bösing C, Kleiner M, Klemenz T, Kluge A, Knospe AG, Kobdaj C, Köhler MK, Kollegger T, Kondratyev A, Kondratyeva N, Kondratyuk E, Konig J, Konigstorfer SA, Konopka PJ, Kornakov G, Koryciak SD, Koska L, Kotliarov A, Kovalenko O, Kovalenko V, Kowalski M, Králik I, Kravčáková A, Kreis L, Krivda M, Krizek F, Krizkova Gajdosova K, Kroesen M, Krüger M, Kryshen E, Krzewicki M, Kučera V, Kuhn C, Kuijer PG, Kumaoka T, Kumar D, Kumar L, Kumar N, Kundu S, Kurashvili P, Kurepin A, Kurepin AB, Kuryakin A, Kushpil S, Kvapil J, Kweon MJ, Kwon JY, Kwon Y, La Pointe SL, La Rocca P, Lai YS, Lakrathok A, Lamanna M, Langoy R, Lapidus K, Larionov P, Laudi E, Lautner L, Lavicka R, Lazareva T, Lea R, Lehrbach J, Lemmon RC, León Monzón I, Lesser ED, Lettrich M, Lévai P, Li X, Li XL, Lien J, Lietava R, Lim B, Lim SH, Lindenstruth V, Lindner A, Lippmann C, Liu A, Liu DH, Liu J, Lofnes IM, Loginov V, Loizides C, Loncar P, Lopez JA, Lopez X, López Torres E, Luhder JR, Lunardon M, Luparello G, Ma YG, Maevskaya A, Mager M, Mahmoud T, Maire A, Malaev M, Malik NM, Malik QW, Malinina L, Mal'Kevich D, Mallick N, Malzacher P, Mandaglio G, Manko V, Manso F, Manzari V, Mao Y, Mareš J, Margagliotti GV, Margotti A, Marín A, Markert C, Marquard M, Martin NA, Martinengo P, Martinez JL, Martínez MI, Martínez García G, Masciocchi S, Masera M, Masoni A, Massacrier L, Mastroserio A, Mathis AM, Matonoha O, Matuoka PFT, Matyja A, Mayer C, Mazuecos AL, Mazzaschi F, Mazzilli M, Mazzoni MA, Mdhluli JE, Mechler AF, Meddi F, Melikyan Y, Menchaca-Rocha A, Meninno E, Menon AS, Meres M, Mhlanga S, Miake Y, Micheletti L, Migliorin LC, Mihaylov DL, Mikhaylov K, Mishra AN, Miśkowiec D, Modak A, Mohanty AP, Mohanty B, Khan MM, Molander MA, Moravcova Z, Mordasini C, Moreira De Godoy DA, Moreno LAP, Morozov I, Morsch A, Mrnjavac T, Muccifora V, Mudnic E, Mühlheim D, Muhuri S, Mulligan JD, Mulliri A, Munhoz MG, Munzer RH, Murakami H, Murray S, Musa L, Musinsky J, Myrcha JW, Naik B, Nair R, Nandi BK, Nania R, Nappi E, Nassirpour AF, Nath A, Nattrass C, Neagu A, Nellen L, Nesbo SV, Neskovic G, Nesterov D, Nielsen BS, Nikolaev S, Nikulin S, Nikulin V, Noferini F, Noh S, Nomokonov P, Norman J, Novitzky N, Nowakowski P, Nyanin A, Nystrand J, Ogino M, Ohlson A, Okorokov VA, Oleniacz J, Oliveira Da Silva AC, Oliver MH, Onnerstad A, Oppedisano C, Ortiz Velasquez A, Osako T, Oskarsson A, Otwinowski J, Oya M, Oyama K, Pachmayer Y, Padhan S, Pagano D, Paić G, Palasciano A, Pan J, Panebianco S, Pareek P, Park J, Parkkila JE, Pathak SP, Patra RN, Paul B, Pei H, Peitzmann T, Peng X, Pereira LG, Pereira Da Costa H, Peresunko D, Perez GM, Perrin S, Pestov Y, Petráček V, Petrovici M, Pezzi RP, Piano S, Pikna M, Pillot P, Pinazza O, Pinsky L, Pinto C, Pisano S, Płoskoń M, Planinic M, Pliquett F, Poghosyan MG, Polichtchouk B, Politano S, Poljak N, Pop A, Porteboeuf-Houssais S, Porter J, Pozdniakov V, Prasad SK, Preghenella R, Prino F, Pruneau CA, Pshenichnov I, Puccio M, Qiu S, Quaglia L, Quishpe RE, Ragoni S, Rakotozafindrabe A, Ramello L, Rami F, Ramirez SAR, Ramos AGT, Rancien TA, Raniwala R, Raniwala S, Räsänen SS, Rath R, Ravasenga I, Read KF, Redelbach AR, Redlich K, Rehman A, Reichelt P, Reidt F, Reme-Ness HA, Renfordt R, Rescakova Z, Reygers K, Riabov A, Riabov V, Richert T, Richter M, Riegler W, Riggi F, Ristea C, Rodríguez Cahuantzi M, Røed K, Rogalev R, Rogochaya E, Rogoschinski TS, Rohr D, Röhrich D, Rojas PF, Rokita PS, Ronchetti F, Rosano A, Rosas ED, Rossi A, Rotondi A, Roy A, Roy P, Roy S, Rubini N, Rueda OV, Rui R, Rumyantsev B, Russek PG, Rustamov A, Ryabinkin E, Ryabov Y, Rybicki A, Rytkonen H, Rzesa W, Saarimaki OAM, Sadek R, Sadovsky S, Saetre J, Šafařík K, Saha SK, Saha S, Sahoo B, Sahoo P, Sahoo R, Sahoo S, Sahu D, Sahu PK, Saini J, Sakai S, Sambyal S, Samsonov V, Sarkar D, Sarkar N, Sarma P, Sarti VM, Sas MHP, Schambach J, Scheid HS, Schiaua C, Schicker R, Schmah A, Schmidt C, Schmidt HR, Schmidt MO, Schmidt M, Schmidt NV, Schmier AR, Schotter R, Schukraft J, Schutz Y, Schwarz K, Schweda K, Scioli G, Scomparin E, Seger JE, Sekiguchi Y, Sekihata D, Selyuzhenkov I, Senyukov S, Seo JJ, Serebryakov D, Šerkšnytė L, Sevcenco A, Shaba TJ, Shabanov A, Shabetai A, Shahoyan R, Shaikh W, Shangaraev A, Sharma A, Sharma H, Sharma M, Sharma N, Sharma S, Sharma U, Sheibani O, Shigaki K, Shimomura M, Shirinkin S, Shou Q, Sibiriak Y, Siddhanta S, Siemiarczuk T, Silva TF, Silvermyr D, Simantathammakul T, Simonetti G, Singh B, Singh R, Singh R, Singh R, Singh VK, Singhal V, Sinha T, Sitar B, Sitta M, Skaali TB, Skorodumovs G, Slupecki M, Smirnov N, Snellings RJM, Soncco C, Song J, Songmoolnak A, Soramel F, Sorensen S, Sputowska I, Stachel J, Stan I, Steffanic PJ, Stiefelmaier SF, Stocco D, Storehaug I, Storetvedt MM, Stylianidis CP, Suaide AAP, Sugitate T, Suire C, Sukhanov M, Suljic M, Sultanov R, Šumbera M, Sumberia V, Sumowidagdo S, Swain S, Szabo A, Szarka I, Tabassam U, Taghavi SF, Taillepied G, Takahashi J, Tambave GJ, Tang S, Tang Z, Tapia Takaki JD, Tarhini M, Tarzila MG, Tauro A, Tejeda Muñoz G, Telesca A, Terlizzi L, Terrevoli C, Tersimonov G, Thakur S, Thomas D, Tieulent R, Tikhonov A, Timmins AR, Tkacik M, Toia A, Topilskaya N, Toppi M, Torales-Acosta F, Tork T, Torres SR, Trifiró A, Tripathy S, Tripathy T, Trogolo S, Trombetta G, Trubnikov V, Trzaska WH, Trzcinski TP, Trzeciak BA, Tumkin A, Turrisi R, Tveter TS, Ullaland K, Uras A, Urioni M, Usai GL, Vala M, Valle N, Vallero S, van der Kolk N, van Doremalen LVR, van Leeuwen M, Vande Vyvre P, Varga D, Varga Z, Varga-Kofarago M, Vargas A, Vasileiou M, Vasiliev A, Vázquez Doce O, Vechernin V, Vercellin E, Vergara Limón S, Vermunt L, Vértesi R, Verweij M, Vickovic L, Vilakazi Z, Villalobos Baillie O, Vino G, Vinogradov A, Virgili T, Vislavicius V, Vodopyanov A, Volkel B, Völkl MA, Voloshin K, Voloshin SA, Volpe G, von Haller B, Vorobyev I, Voscek D, Vozniuk N, Vrláková J, Wagner B, Wang C, Wang D, Weber M, Weelden RJGV, Wegrzynek A, Wenzel SC, Wessels JP, Wiechula J, Wikne J, Wilk G, Wilkinson J, Willems GA, Windelband B, Winn M, Witt WE, Wright JR, Wu W, Wu Y, Xu R, Yadav AK, Yalcin S, Yamaguchi Y, Yamakawa K, Yang S, Yano S, Yin Z, Yokoyama H, Yoo IK, Yoon JH, Yuan S, Yuncu A, Zaccolo V, Zampolli C, Zanoli HJC, Zardoshti N, Zarochentsev A, Závada P, Zaviyalov N, Zhalov M, Zhang B, Zhang S, Zhang X, Zhang Y, Zherebchevskii V, Zhi Y, Zhigareva N, Zhou D, Zhou Y, Zhu J, Zhu Y, Zichichi A, Zinovjev G, Zurlo N. Polarization of Λ and Λ[over ¯] Hyperons along the Beam Direction in Pb-Pb Collisions at sqrt[s]_{NN}=5.02 TeV. PHYSICAL REVIEW LETTERS 2022; 128:172005. [PMID: 35570422 DOI: 10.1103/physrevlett.128.172005] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/03/2021] [Revised: 01/04/2022] [Accepted: 03/16/2022] [Indexed: 06/15/2023]
Abstract
The polarization of the Λ and Λ[over ¯] hyperons along the beam (z) direction, P_{z}, has been measured in Pb-Pb collisions at sqrt[s_{NN}]=5.02 TeV recorded with ALICE at the Large Hadron Collider (LHC). The main contribution to P_{z} comes from elliptic flow-induced vorticity and can be characterized by the second Fourier sine coefficient P_{z,s2}=⟨P_{z}sin(2φ-2Ψ_{2})⟩, where φ is the hyperon azimuthal emission angle and Ψ_{2} is the elliptic flow plane angle. We report the measurement of P_{z,s2} for different collision centralities and in the 30%-50% centrality interval as a function of the hyperon transverse momentum and rapidity. The P_{z,s2} is positive similarly as measured by the STAR Collaboration in Au-Au collisions at sqrt[s_{NN}]=200 GeV, with somewhat smaller amplitude in the semicentral collisions. This is the first experimental evidence of a nonzero hyperon P_{z} in Pb-Pb collisions at the LHC. The comparison of the measured P_{z,s2} with the hydrodynamic model calculations shows sensitivity to the competing contributions from thermal and the recently found shear-induced vorticity, as well as to whether the polarization is acquired at the quark-gluon plasma or the hadronic phase.
Collapse
|
73
|
Ikar N, Sommer S, Schmidt M, Löwe C, Kasten S, Gavrilov B, Hunzelar C, Bockheim F, Paños-Willuhn J, Offenberg L, Oberholz M, Weltermann B. Unemployed individuals contact GPs more frequently but report lower satisfaction: results of the population-based DEGS1 and the GPCare-1 patient survey. Sci Rep 2022; 12:6670. [PMID: 35461341 PMCID: PMC9035161 DOI: 10.1038/s41598-022-10621-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2021] [Accepted: 04/08/2022] [Indexed: 11/09/2022] Open
Abstract
Unemployment is associated with a variety of adverse health-related outcomes, yet little data on primary care services for this risk group exist. Using data from two surveys, we analyzed the frequency of GP contacts and patients' experiences with GPs comparing unemployed with employed individuals. Data of the German Health Interview and Examination Survey for Adults (DEGS1), a nationwide cross-sectional study (n = 8151), were analyzed regarding associations between employment status and the number of GP visits. The General Practice Care-1 study (GPCare-1), a cross-sectional questionnaire survey (n = 813), evaluated patients' communication with their GP. Data were collected from June to August 2020 in 12 teaching practices affiliated with our university. The statistical analysis included individuals of working age (18-64 years old) (DEGS1 n = 5659, GPCare-1 n = 587). In both studies, working age subpopulations were analyzed (DEGS1: n = 5659 of 8151, GPCare-1: n = 587 of 813). In DEGS1, the prevalence of unemployment was 6.5% (n = 372). Unemployed individuals had more GP contacts in the last 12 months (4.50 vs. 2.86, p < 0.001). In the GPCare-1 study, unemployed individuals (6.6%, n = 39) were significantly less satisfied with GP communication: enough space in consultations (42.9% vs. 60.3%, p = 0.043), feeling comfortable to address sensitive topics (44.1% vs. 65.9%, p = 0.010), problems taken very seriously by GP (48.6% vs. 70.6%, p = 0.007). Yet, they were more willing to accept GPs' help for psychosocial burdens (67.6% vs. 47.6%, p = 0.024). GPs should be aware that patients with unemployment wish more support to cope with their burdening situation.
Collapse
|
74
|
Wollak B, Doronkin D, Espinoza D, Sheppard T, Korup O, Schmidt M, Alizadefanaloo S, Rosowski F, Schroer C, Grunwaldt JD, Horn R. Exploring catalyst dynamics in a fixed bed reactor by correlative operando spatially-resolved structure-activity profiling. J Catal 2022. [DOI: 10.1016/j.jcat.2021.08.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
75
|
Acharya S, Adamová D, Adler A, Aglieri Rinella G, Agnello M, Agrawal N, Ahammed Z, Ahmad S, Ahn SU, Ahuja I, Akbar Z, Akindinov A, Al-Turany M, Alam SN, Aleksandrov D, Alessandro B, Alfanda HM, Alfaro Molina R, Ali B, Ali Y, Alici A, Alizadehvandchali N, Alkin A, Alme J, Alt T, Altenkamper L, Altsybeev I, Anaam MN, Andrei C, Andreou D, Andronic A, Angeletti M, Anguelov V, Antinori F, Antonioli P, Anuj C, Apadula N, Aphecetche L, Appelshäuser H, Arcelli S, Arnaldi R, Arsene IC, Arslandok M, Augustinus A, Averbeck R, Aziz S, Azmi MD, Badalà A, Baek YW, Bai X, Bailhache R, Bailung Y, Bala R, Balbino A, Baldisseri A, Balis B, Ball M, Banerjee D, Barbera R, Barioglio L, Barlou M, Barnaföldi GG, Barnby LS, Barret V, Bartels C, Barth K, Bartsch E, Baruffaldi F, Bastid N, Basu S, Batigne G, Batyunya B, Bauri D, Bazo Alba JL, Bearden IG, Beattie C, Belikov I, Bell Hechavarria ADC, Bellini F, Bellwied R, Belokurova S, Belyaev V, Bencedi G, Beole S, Bercuci A, Berdnikov Y, Berdnikova A, Bergmann L, Besoiu MG, Betev L, Bhaduri PP, Bhasin A, Bhat IR, Bhat MA, Bhattacharjee B, Bhattacharya P, Bianchi L, Bianchi N, Bielčík J, Bielčíková J, Biernat J, Bilandzic A, Biro G, Biswas S, Blair JT, Blau D, Blidaru MB, Blume C, Boca G, Bock F, Bogdanov A, Boi S, Bok J, Boldizsár L, Bolozdynya A, Bombara M, Bond PM, Bonomi G, Borel H, Borissov A, Bossi H, Botta E, Bratrud L, Braun-Munzinger P, Bregant M, Broz M, Bruno GE, Buckland MD, Budnikov D, Buesching H, Bufalino S, Bugnon O, Buhler P, Buthelezi Z, Butt JB, Bysiak SA, Cai M, Caines H, Caliva A, Calvo Villar E, Camacho JMM, Camacho RS, Camerini P, Canedo FDM, Carnesecchi F, Caron R, Castillo Castellanos J, Casula EAR, Catalano F, Ceballos Sanchez C, Chakraborty P, Chandra S, Chapeland S, Chartier M, Chattopadhyay S, Chattopadhyay S, Chauvin A, Chavez TG, Cheng T, Cheshkov C, Cheynis B, Chibante Barroso V, Chinellato DD, Cho S, Chochula P, Christakoglou P, Christensen CH, Christiansen P, Chujo T, Cicalo C, Cifarelli L, Cindolo F, Ciupek MR, Clai G, Cleymans J, Colamaria F, Colburn JS, Colella D, Collu A, Colocci M, Concas M, Conesa Balbastre G, Conesa Del Valle Z, Contin G, Contreras JG, Coquet ML, Cormier TM, Cortese P, Cosentino MR, Costa F, Costanza S, Crochet P, Cruz-Torres R, Cuautle E, Cui P, Cunqueiro L, Dainese A, Danisch MC, Danu A, Das I, Das P, Das P, Das S, Dash S, De S, De Caro A, de Cataldo G, De Cilladi L, de Cuveland J, De Falco A, De Gruttola D, De Marco N, De Martin C, De Pasquale S, Deb S, Degenhardt HF, Deja KR, Dello Stritto L, Delsanto S, Deng W, Dhankher P, Di Bari D, Di Mauro A, Diaz RA, Dietel T, Ding Y, Divià R, Dixit DU, Djuvsland Ø, Dmitrieva U, Do J, Dobrin A, Dönigus B, Dordic O, Dubey AK, Dubla A, Dudi S, Dukhishyam M, Dupieux P, Dzalaiova N, Eder TM, Ehlers RJ, Eikeland VN, Eisenhut F, Elia D, Erazmus B, Ercolessi F, Erhardt F, Erokhin A, Ersdal MR, Espagnon B, Eulisse G, Evans D, Evdokimov S, Fabbietti L, Faggin M, Faivre J, Fan F, Fantoni A, Fasel M, Fecchio P, Feliciello A, Feofilov G, Fernández Téllez A, Ferrero A, Ferretti A, Feuillard VJG, Figiel J, Filchagin S, Finogeev D, Fionda FM, Fiorenza G, Flor F, Flores AN, Foertsch S, Foka P, Fokin S, Fragiacomo E, Frajna E, Fuchs U, Funicello N, Furget C, Furs A, Gaardhøje JJ, Gagliardi M, Gago AM, Gal A, Galvan CD, Ganoti P, Garabatos C, Garcia JRA, Garcia-Solis E, Garg K, Gargiulo C, Garibli A, Garner K, Gasik P, Gauger EF, Gautam A, Gay Ducati MB, Germain M, Ghosh P, Ghosh SK, Giacalone M, Gianotti P, Giubellino P, Giubilato P, Glaenzer AMC, Glässel P, Goh DJQ, Gonzalez V, González-Trueba LH, Gorbunov S, Gorgon M, Görlich L, Gotovac S, Grabski V, Graczykowski LK, Greiner L, Grelli A, Grigoras C, Grigoriev V, Grigoryan S, Groettvik OS, Grosa F, Grosse-Oetringhaus JF, Grosso R, Guardiano GG, Guernane R, Guilbaud M, Gulbrandsen K, Gunji T, Guo W, Gupta A, Gupta R, Guzman SP, Gyulai L, Habib MK, Hadjidakis C, Halimoglu G, Hamagaki H, Hamar G, Hamid M, Hannigan R, Haque MR, Harlenderova A, Harris JW, Harton A, Hasenbichler JA, Hassan H, Hatzifotiadou D, Hauer P, Havener LB, Hayashi S, Heckel ST, Hellbär E, Helstrup H, Herman T, Hernandez EG, Herrera Corral G, Herrmann F, Hetland KF, Hillemanns H, Hills C, Hippolyte B, Hofman B, Hohlweger B, Honermann J, Hong GH, Horak D, Hornung S, Horzyk A, Hosokawa R, Hou Y, Hristov P, Hughes C, Huhn P, Humanic TJ, Hushnud H, Husova LA, Hutson A, Hutter D, Iddon JP, Ilkaev R, Ilyas H, Inaba M, Innocenti GM, Ippolitov M, Isakov A, Islam MS, Ivanov M, Ivanov V, Izucheev V, Jablonski M, Jacak B, Jacazio N, Jacobs PM, Jadlovska S, Jadlovsky J, Jaelani S, Jahnke C, Jakubowska MJ, Jalotra A, Janik MA, Janson T, Jercic M, Jevons O, Jimenez AAP, Jonas F, Jones PG, Jowett JM, Jung J, Jung M, Junique A, Jusko A, Kaewjai J, Kalinak P, Kalweit A, Kaplin V, Kar S, Karasu Uysal A, Karatovic D, Karavichev O, Karavicheva T, Karczmarczyk P, Karpechev E, Kazantsev A, Kebschull U, Keidel R, Keijdener DLD, Keil M, Ketzer B, Khabanova Z, Khan AM, Khan S, Khanzadeev A, Kharlov Y, Khatun A, Khuntia A, Kileng B, Kim B, Kim C, Kim DJ, Kim EJ, Kim J, Kim JS, Kim J, Kim J, Kim J, Kim M, Kim S, Kim T, Kirsch S, Kisel I, Kiselev S, Kisiel A, Kitowski JP, Klay JL, Klein J, Klein S, Klein-Bösing C, Kleiner M, Klemenz T, Kluge A, Knospe AG, Kobdaj C, Köhler MK, Kollegger T, Kondratyev A, Kondratyeva N, Kondratyuk E, Konig J, Konigstorfer SA, Konopka PJ, Kornakov G, Koryciak SD, Koska L, Kotliarov A, Kovalenko O, Kovalenko V, Kowalski M, Králik I, Kravčáková A, Kreis L, Krivda M, Krizek F, Krizkova Gajdosova K, Kroesen M, Krüger M, Kryshen E, Krzewicki M, Kučera V, Kuhn C, Kuijer PG, Kumaoka T, Kumar D, Kumar L, Kumar N, Kundu S, Kurashvili P, Kurepin A, Kurepin AB, Kuryakin A, Kushpil S, Kvapil J, Kweon MJ, Kwon JY, Kwon Y, La Pointe SL, La Rocca P, Lai YS, Lakrathok A, Lamanna M, Langoy R, Lapidus K, Larionov P, Laudi E, Lautner L, Lavicka R, Lazareva T, Lea R, Lehrbach J, Lemmon RC, León Monzón I, Lesser ED, Lettrich M, Lévai P, Li X, Li XL, Lien J, Lietava R, Lim B, Lim SH, Lindenstruth V, Lindner A, Lippmann C, Liu A, Liu DH, Liu J, Lofnes IM, Loginov V, Loizides C, Loncar P, Lopez JA, Lopez X, López Torres E, Luhder JR, Lunardon M, Luparello G, Ma YG, Maevskaya A, Mager M, Mahmoud T, Maire A, Malaev M, Malik NM, Malik QW, Malinina L, Mal'Kevich D, Mallick N, Malzacher P, Mandaglio G, Manko V, Manso F, Manzari V, Mao Y, Mareš J, Margagliotti GV, Margotti A, Marín A, Markert C, Marquard M, Martin NA, Martinengo P, Martinez JL, Martínez MI, Martínez García G, Masciocchi S, Masera M, Masoni A, Massacrier L, Mastroserio A, Mathis AM, Matonoha O, Matuoka PFT, Matyja A, Mayer C, Mazuecos AL, Mazzaschi F, Mazzilli M, Mazzoni MA, Mdhluli JE, Mechler AF, Meddi F, Melikyan Y, Menchaca-Rocha A, Meninno E, Menon AS, Meres M, Mhlanga S, Miake Y, Micheletti L, Migliorin LC, Mihaylov DL, Mikhaylov K, Mishra AN, Miśkowiec D, Modak A, Mohanty AP, Mohanty B, Mohisin Khan M, Molander MA, Moravcova Z, Mordasini C, Moreira De Godoy DA, Moreno LAP, Morozov I, Morsch A, Mrnjavac T, Muccifora V, Mudnic E, Mühlheim D, Muhuri S, Mulligan JD, Mulliri A, Munhoz MG, Munzer RH, Murakami H, Murray S, Musa L, Musinsky J, Myrcha JW, Naik B, Nair R, Nandi BK, Nania R, Nappi E, Nassirpour AF, Nath A, Nattrass C, Neagu A, Nellen L, Nesbo SV, Neskovic G, Nesterov D, Nielsen BS, Nikolaev S, Nikulin S, Nikulin V, Noferini F, Noh S, Nomokonov P, Norman J, Novitzky N, Nowakowski P, Nyanin A, Nystrand J, Ogino M, Ohlson A, Okorokov VA, Oleniacz J, Oliveira Da Silva AC, Oliver MH, Onnerstad A, Oppedisano C, Ortiz Velasquez A, Osako T, Oskarsson A, Otwinowski J, Oya M, Oyama K, Pachmayer Y, Padhan S, Pagano D, Paić G, Palasciano A, Pan J, Panebianco S, Pareek P, Park J, Parkkila JE, Pathak SP, Patra RN, Paul B, Pei H, Peitzmann T, Peng X, Pereira LG, Pereira Da Costa H, Peresunko D, Perez GM, Perrin S, Pestov Y, Petráček V, Petrovici M, Pezzi RP, Piano S, Pikna M, Pillot P, Pinazza O, Pinsky L, Pinto C, Pisano S, Płoskoń M, Planinic M, Pliquett F, Poghosyan MG, Polichtchouk B, Politano S, Poljak N, Pop A, Porteboeuf-Houssais S, Porter J, Pozdniakov V, Prasad SK, Preghenella R, Prino F, Pruneau CA, Pshenichnov I, Puccio M, Qiu S, Quaglia L, Quishpe RE, Ragoni S, Rakotozafindrabe A, Ramello L, Rami F, Ramirez SAR, Ramos AGT, Rancien TA, Raniwala R, Raniwala S, Räsänen SS, Rath R, Ravasenga I, Read KF, Redelbach AR, Redlich K, Rehman A, Reichelt P, Reidt F, Reme-Ness HA, Renfordt R, Rescakova Z, Reygers K, Riabov A, Riabov V, Richert T, Richter M, Riegler W, Riggi F, Ristea C, Rodríguez Cahuantzi M, Røed K, Rogalev R, Rogochaya E, Rogoschinski TS, Rohr D, Röhrich D, Rojas PF, Rokita PS, Ronchetti F, Rosano A, Rosas ED, Rossi A, Rotondi A, Roy A, Roy P, Roy S, Rubini N, Rueda OV, Rui R, Rumyantsev B, Russek PG, Rustamov A, Ryabinkin E, Ryabov Y, Rybicki A, Rytkonen H, Rzesa W, Saarimaki OAM, Sadek R, Sadovsky S, Saetre J, Šafařík K, Saha SK, Saha S, Sahoo B, Sahoo P, Sahoo R, Sahoo S, Sahu D, Sahu PK, Saini J, Sakai S, Sambyal S, Samsonov V, Sarkar D, Sarkar N, Sarma P, Sarti VM, Sas MHP, Schambach J, Scheid HS, Schiaua C, Schicker R, Schmah A, Schmidt C, Schmidt HR, Schmidt MO, Schmidt M, Schmidt NV, Schmier AR, Schotter R, Schukraft J, Schutz Y, Schwarz K, Schweda K, Scioli G, Scomparin E, Seger JE, Sekiguchi Y, Sekihata D, Selyuzhenkov I, Senyukov S, Seo JJ, Serebryakov D, Šerkšnytė L, Sevcenco A, Shaba TJ, Shabanov A, Shabetai A, Shahoyan R, Shaikh W, Shangaraev A, Sharma A, Sharma H, Sharma M, Sharma N, Sharma S, Sharma U, Sheibani O, Shigaki K, Shimomura M, Shirinkin S, Shou Q, Sibiriak Y, Siddhanta S, Siemiarczuk T, Silva TF, Silvermyr D, Simonetti G, Singh B, Singh R, Singh R, Singh R, Singh VK, Singhal V, Sinha T, Sitar B, Sitta M, Skaali TB, Skorodumovs G, Slupecki M, Smirnov N, Snellings RJM, Soncco C, Song J, Songmoolnak A, Soramel F, Sorensen S, Sputowska I, Stachel J, Stan I, Steffanic PJ, Stiefelmaier SF, Stocco D, Storehaug I, Storetvedt MM, Stylianidis CP, Suaide AAP, Sugitate T, Suire C, Sukhanov M, Suljic M, Sultanov R, Šumbera M, Sumberia V, Sumowidagdo S, Swain S, Szabo A, Szarka I, Tabassam U, Taghavi SF, Taillepied G, Takahashi J, Tambave GJ, Tang S, Tang Z, Tapia Takaki JD, Tarhini M, Tarzila MG, Tauro A, Tejeda Muñoz G, Telesca A, Terlizzi L, Terrevoli C, Tersimonov G, Thakur S, Thomas D, Tieulent R, Tikhonov A, Timmins AR, Tkacik M, Toia A, Topilskaya N, Toppi M, Torales-Acosta F, Tork T, Torres SR, Trifiró A, Tripathy S, Tripathy T, Trogolo S, Trombetta G, Trubnikov V, Trzaska WH, Trzcinski TP, Trzeciak BA, Tumkin A, Turrisi R, Tveter TS, Ullaland K, Uras A, Urioni M, Usai GL, Vala M, Valle N, Vallero S, van der Kolk N, van Doremalen LVR, van Leeuwen M, Vande Vyvre P, Varga D, Varga Z, Varga-Kofarago M, Vargas A, Vasileiou M, Vasiliev A, Vázquez Doce O, Vechernin V, Vercellin E, Vergara Limón S, Vermunt L, Vértesi R, Verweij M, Vickovic L, Vilakazi Z, Villalobos Baillie O, Vino G, Vinogradov A, Virgili T, Vislavicius V, Vodopyanov A, Volkel B, Völkl MA, Voloshin K, Voloshin SA, Volpe G, von Haller B, Vorobyev I, Voscek D, Vozniuk N, Vrláková J, Wagner B, Wang C, Wang D, Weber M, Weelden RJGV, Wegrzynek A, Wenzel SC, Wessels JP, Wiechula J, Wikne J, Wilk G, Wilkinson J, Willems GA, Windelband B, Winn M, Witt WE, Wright JR, Wu W, Wu Y, Xu R, Yadav AK, Yalcin S, Yamaguchi Y, Yamakawa K, Yang S, Yano S, Yin Z, Yokoyama H, Yoo IK, Yoon JH, Yuan S, Yuncu A, Zaccolo V, Zampolli C, Zanoli HJC, Zardoshti N, Zarochentsev A, Závada P, Zaviyalov N, Zhalov M, Zhang B, Zhang S, Zhang X, Zhang Y, Zherebchevskii V, Zhi Y, Zhigareva N, Zhou D, Zhou Y, Zhu J, Zhu Y, Zichichi A, Zinovjev G, Zurlo N. Measurement of the Groomed Jet Radius and Momentum Splitting Fraction in pp and Pb-Pb Collisions at sqrt[s_{NN}]=5.02 TeV. PHYSICAL REVIEW LETTERS 2022; 128:102001. [PMID: 35333086 DOI: 10.1103/physrevlett.128.102001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/25/2021] [Revised: 11/29/2021] [Accepted: 02/10/2022] [Indexed: 06/14/2023]
Abstract
This article presents groomed jet substructure measurements in pp and Pb-Pb collisions at sqrt[s_{NN}]=5.02 TeV with the ALICE detector. The soft drop grooming algorithm provides access to the hard parton splittings inside a jet by removing soft wide-angle radiation. We report the groomed jet momentum splitting fraction, z_{g}, and the (scaled) groomed jet radius, θ_{g}. Charged-particle jets are reconstructed at midrapidity using the anti-k_{T} algorithm with resolution parameters R=0.2 and R=0.4. In heavy-ion collisions, the large underlying event poses a challenge for the reconstruction of groomed jet observables, since fluctuations in the background can cause groomed parton splittings to be misidentified. By using strong grooming conditions to reduce this background, we report these observables fully corrected for detector effects and background fluctuations for the first time. A narrowing of the θ_{g} distribution in Pb-Pb collisions compared to pp collisions is seen, which provides direct evidence of the modification of the angular structure of jets in the quark-gluon plasma. No significant modification of the z_{g} distribution in Pb-Pb collisions compared to pp collisions is observed. These results are compared with a variety of theoretical models of jet quenching, and provide constraints on jet energy-loss mechanisms and coherence effects in the quark-gluon plasma.
Collapse
|